Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence

Role of Liraglutide in weight management and... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/14-979" }, "headline": "Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical...", "datePublished": "2025-09-24T14:15:30", "dateModified": "2026-04-24T06:59:47", "author": [ { "@type": "Person", "name": "Shravya Shetty" }, { "@type": "Person", "name": "Mouna Bannur Karunakara" }, { "@type": "Person", "name": "Ravi Ram Kristipati" }, { "@type": "Person", "name": "Guruprasad Kalthur" }, { "@type": "Person", "name": "Sandhya Kumari" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": "Obesity and polycystic ovary syndrome (PCOS) in women are associated with significant reproductive dysfunction, manifesting as hormonal imbalances, anovulation, and subfertility. These conditions not only impair reproductive outcomes but also contribute to a reduced quality of life. Crucially, obesity and PCOS share a bidirectional relationship. While obesity can trigger and worsen PCOS manifestations, the convergence of these two conditions has contributed significantly to the growing incidence of female infertility. This review critically examines liraglutide’s mechanistic role and therapeutic potential in mediating metabolic restoration and improving the fertility outcomes in women burdened by obesity and PCOS. A literature search was conducted in original databases from inception until March 2025 in PubMed, Google Scholar, Cochrane Library, Scopus, and Web of Science using the following keywords pertinently: “GLP-1R”, “liraglutide”, “female reproductive system”, “polycystic ovarian syndrome”, “ovarian function”, and “pregnancy outcomes”. Accumulated evidence suggests that liraglutide promotes greater weight loss and improves reproductive outcomes in women with obesity and PCOS by regulating endocrine parameters, reducing systemic inflammation, restoring menstrual cyclicity, and supporting folliculogenesis. It improves reproductive outcomes by increasing natural conception rates and improving responses to assisted reproductive techniques (ART). However, with all the positive outcomes, the major limitations of using this drug for weight loss are the need for daily subcutaneous injections, cost, and gastrointestinal adverse effects. Long-term assessment of the sustained efficacy and impact on reproductive outcomes, including the pattern of ovulation and offspring health, is warranted. This review consolidated present findings and emphasized areas for further exploration to better inform clinical decision-making and future research directions." } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/14-979", "name": "Role of Liraglutide in weight management and reproductive health in..." } } ] } Home Browse Role of Liraglutide in weight management and reproductive health in... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Shetty S, Bannur Karunakara M, Kristipati RR et al. Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.12688/f1000research.167998.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Review Revised Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] Shravya Shetty 1 , Mouna Bannur Karunakara 1 , Ravi Ram Kristipati 2 , Guruprasad Kalthur 3 , Sandhya Kumari https://orcid.org/0000-0002-3589-3289 1 Shravya Shetty 1 , Mouna Bannur Karunakara 1 , [...] Ravi Ram Kristipati 2 , Guruprasad Kalthur 3 , Sandhya Kumari https://orcid.org/0000-0002-3589-3289 1 PUBLISHED 24 Apr 2026 Author details Author details 1 Division of Reproductive Biology, Department of Reproductive Science, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India 2 Embryotoxicology Laboratory, Environmental Toxicology Group, Indian Institute of Toxicology Research- (CSIR-IITR), Lucknow, Uttar Pradesh, 226001, India 3 Sree Mookambika Centre for Research and Innovation, Sree Mookambika Institutes, Padanilam, Kulasekharam, Tamil Nadu, 629161, India Shravya Shetty Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing Mouna Bannur Karunakara Roles: Investigation, Methodology, Writing – Review & Editing Ravi Ram Kristipati Roles: Methodology, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Guruprasad Kalthur Roles: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing Sandhya Kumari Roles: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS This article is included in the Manipal Academy of Higher Education gateway. Abstract Obesity and polycystic ovary syndrome (PCOS) in women are associated with significant reproductive dysfunction, manifesting as hormonal imbalances, anovulation, and subfertility. These conditions not only impair reproductive outcomes but also contribute to a reduced quality of life. Crucially, obesity and PCOS share a bidirectional relationship. While obesity can trigger and worsen PCOS manifestations, the convergence of these two conditions has contributed significantly to the growing incidence of female infertility. This review critically examines liraglutide’s mechanistic role and therapeutic potential in mediating metabolic restoration and improving the fertility outcomes in women burdened by obesity and PCOS. A literature search was conducted in original databases from inception until March 2025 in PubMed, Google Scholar, Cochrane Library, Scopus, and Web of Science using the following keywords pertinently: “GLP-1R”, “liraglutide”, “female reproductive system”, “polycystic ovarian syndrome”, “ovarian function”, and “pregnancy outcomes”. Accumulated evidence suggests that liraglutide promotes greater weight loss and improves reproductive outcomes in women with obesity and PCOS by regulating endocrine parameters, reducing systemic inflammation, restoring menstrual cyclicity, and supporting folliculogenesis. It improves reproductive outcomes by increasing natural conception rates and improving responses to assisted reproductive techniques (ART). However, with all the positive outcomes, the major limitations of using this drug for weight loss are the need for daily subcutaneous injections, cost, and gastrointestinal adverse effects. Long-term assessment of the sustained efficacy and impact on reproductive outcomes, including the pattern of ovulation and offspring health, is warranted. This review consolidated present findings and emphasized areas for further exploration to better inform clinical decision-making and future research directions. READ ALL READ LESS Keywords Obesity, PCOS, Insulin resistance, Hyperandrogenism, Liraglutide, Ovarian Function, Fertility Corresponding Author(s) Guruprasad Kalthur ( [email protected] ) Sandhya Kumari ( [email protected] ) Close Corresponding authors: Guruprasad Kalthur, Sandhya Kumari Competing interests: No competing interests were disclosed. Grant information: The work is funded by the Indian Council of Medical Research, Government of India (Grant no. DDR/IIRP-23/1021). Sandhya Kumari M V. acknowledges partial support from intramural grant, Manipal Academy of Higher Education, Manipal. Dr. TMA Pai scholarship, Manipal Academy of Higher Education, Manipal awarded to Shravya Shetty is thankfully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2026 Shetty S et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Shetty S, Bannur Karunakara M, Kristipati RR et al. Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.12688/f1000research.167998.2 ) First published: 24 Sep 2025, 14 :979 ( https://doi.org/10.12688/f1000research.167998.1 ) Latest published: 24 Apr 2026, 14 :979 ( https://doi.org/10.12688/f1000research.167998.2 ) Revised Amendments from Version 1 This revised manuscript has been updated to enhance methodological transparency, critical synthesis, and narrative focus. Specifically, the methods section now defines the work as a narrative review utilizing a structured, hierarchical selection workflow with specified temporal limits (inception to March 2025) and a dual-researcher independent screening process to minimize selection bias. We have transitioned from a descriptive summary of clinical trials to an analytical framework that addresses study heterogeneity, confounding factors, and methodological weaknesses, while restructuring the discussion to feature a comparative analysis of liraglutide and standard of care therapies. To sharpen the narrative focus, neuroprotection and bone metabolism has been condensed to prioritize reproductive endocrinology and PCOS-associated infertility. Furthermore, previously isolated sections on microbiome modulation and molecular pathways have been integrated into a unified conceptual model to illustrate translational potential. Finally, the conclusions have been tempered to reflect clinical uncertainties, explicitly acknowledging the current lack of longitudinal live-birth data. This revised manuscript has been updated to enhance methodological transparency, critical synthesis, and narrative focus. Specifically, the methods section now defines the work as a narrative review utilizing a structured, hierarchical selection workflow with specified temporal limits (inception to March 2025) and a dual-researcher independent screening process to minimize selection bias. We have transitioned from a descriptive summary of clinical trials to an analytical framework that addresses study heterogeneity, confounding factors, and methodological weaknesses, while restructuring the discussion to feature a comparative analysis of liraglutide and standard of care therapies. To sharpen the narrative focus, neuroprotection and bone metabolism has been condensed to prioritize reproductive endocrinology and PCOS-associated infertility. Furthermore, previously isolated sections on microbiome modulation and molecular pathways have been integrated into a unified conceptual model to illustrate translational potential. Finally, the conclusions have been tempered to reflect clinical uncertainties, explicitly acknowledging the current lack of longitudinal live-birth data. See the authors' detailed response to the review by Dr. Abilash V G READ REVIEWER RESPONSES Introduction Obesity has expeditiously transitioned from a lifestyle-associated metabolic disorder into a global epidemic and a deeply ingrained pathological condition. It is defined by a body mass index (BMI) exceeding 35 kg/m 2 , while overweight is defined as a BMI above 25 kg/m 2 . 1 As highlighted by the National Family Health Survey (2019–2021), the demographic burden of obesity in India is more evident among women, with prevalence rates of abdominal obesity reaching 40% in women compared to 12% in men. 2 The consequences of obesity have extended far beyond being mere metabolic syndrome, with it now recognized as a significant contributor to a spectrum of multisystemic disorders, including respiratory, gastrointestinal (GI), endocrine, cardiovascular, musculoskeletal, and psychological disorders that collectively lower the quality of life. 3 Sharing a similar etiology with obesity, polycystic ovarian syndrome (PCOS) is the most common endocrine-metabolic disorder negatively impacting women of reproductive age, characterized by chronic anovulation, hyperandrogenism, chronic low-grade inflammation, insulin resistance, and altered hormonal profiles, including elevated luteinizing hormone (LH), reduced follicle stimulating hormone (FSH), and imbalances in estrogen and insulin levels. 4 – 6 Around 50% of the women with PCOS are overweight or obese, and existing comorbidities of reproductive dysfunction and metabolic disturbances in both obesity and PCOS create a vicious cycle, promoting menstrual irregularities, hormonal imbalances, and subfertility. Adding to this, Infertility contributes to psychological distress, unhealthy behaviors, and additional weight gain, further compounding the cycle. 7 – 10 Additionally, central obesity has been robustly linked to a gamut of reproductive endocrinopathies, leading to poor fertility outcomes (both assisted and spontaneous). 11 Therefore, early, long-term, and persistent intervention to address the condition becomes imperative. Weight loss remains a first approach and cornerstone strategy for managing both PCOS and obesity-induced infertility. Even the slightest weight loss of 5 to 6% has shown considerable benefits in restoring ovulatory cycles, increasing sex hormone-binding globulin (SHBG) levels, improving insulin sensitivity, and enhancing assisted reproductive techniques (ART) outcomes. 12 – 14 Weight reduction by lifestyle-based interventions, such as diet restriction, and physical activity, is clinically effective, but is often hampered by poor adherence, limited access to resources, and socioeconomic barriers, leaving a significant gap in treatment success and sustainability. Pharmacotherapy agents, particularly liraglutide, have come up as a compelling adjunct. Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), was originally developed for glycemic control and weight management. Acting through the entero-insular axis, it enhances insulin secretion, delays gastric emptying, reduces appetite, and facilitates weight loss. 15 Extending therapeutic benefits beyond systemic metabolic effects, its action in improving reproductive health is better emphasized by the presence of glucagon-like peptide-1 receptors (GLP-1R) in ovarian granulosa cells, signalling at direct ovarian action. 16 These observations open new treatment approaches for addressing the hormonal and metabolic dysfunction mutual with PCOS, obesity, and resultant infertility. Despite well-structured and employed public health strategies and awareness, obesity and PCOS conditions continue to prevail, with wide-reaching reproductive and endocrine implications resulting in a low quality of life. With its outstanding advantageous metabolic and reproductive outcomes, liraglutide presents a novel, practical, and non-surgical intervention in this complicated and, challenging clinical space. This review aims to critically shed light on liraglutide’s mechanistic role and therapeutic potential evidenced by murine models and clinical trials, particularly its ability to mediate metabolic restoration and improve fertility outcomes in women affected by obesity and PCOS. Methods A comprehensive literature search was conducted across four databases: PubMed, Cochrane Library, Scopus, and Web of Science, covering articles published through inception to March 2025. This review adopts a narrative synthesis approach to critically evaluate the mechanistic role and therapeutic potential of liraglutide in managing metabolic and reproductive dysfunction in women with obesity and PCOS. The search strategy employed a combination of keywords: “obesity”, “female reproductive system”, “PCOS”, “anti-obesity treatment”, “GLP-1RA”, “liraglutide”, “ovarian function”, and “pregnancy outcomes”. To ensure reliability and to minimise bias, two independent researchers screened title, abstract and full-text articles. The literature search strategy is illustrated in detail in Figure 1 . Inclusion criteria focused on relevant articles that provided insights into mechanistic and clinical trials evaluating liraglutide’s efficacy. Non-English articles, opinion pieces, and anecdotal evidence were excluded. Of the 130 articles identified through database searches, a significant portion is categorised as contextual literature to provide historical background and support the discussion of biological mechanisms. To maintain a rigorous translational focus, the review also consists of eight clinical studies providing human evidence that establishes the real-world efficacy of liraglutide in managing the reproductive-metabolic intersection of obesity and PCOS. Figure 1. Flow diagram illustrating the study selection process for the evidence synthesis. Records were identified through database searching, screened based on title and abstract, and assessed for eligibility. Studies were excluded due to lack of relevance to GLP-1 receptor agonists, liraglutide-related metabolic, reproductive, and mechanistic outcomes. A total of 130 articles were included, comprising 122 contextual (background/mechanistic) studies and 8 core clinical studies. Bidirectional relationship of obesity and PCOS and reproductive health Even though obesity and PCOS are not the clinical diagnostic characteristics of each other’s conditions, the coexistence is about 30–70%. 17 The strong bidirectional network of metabolic, inflammatory, and endocrine disturbance between these two conditions further perpetuates the reproductive dysfunction synergistically. Obesity poses a significant risk for developing insulin resistance by triggering chronic low-grade systemic and local inflammation, which is a key diagnostic criterion for PCOS. 18 , 19 Manifested hyperinsulinemia elevates androgen levels by regulating hepatic SHBG production and raising ovarian androgen levels. 20 , 21 Meanwhile, PCOS promotes visceral fat accumulation through hyperandrogenism, a major driver of hyperinsulinemia. Further, obese or PCOS conditions, dysregulated hypertrophy and hyperplasia of adipose tissues actively drive chronic low-grade inflammation. 22 Collectively, these factors disrupt hormonal cascade, interfering with steroidogenesis, impairing folliculogenesis, and further worsening metabolic dysfunction, ultimately contributing to infertility in women with obesity and/or PCOS. 23 – 26 In addition, obesity may impact fertility by many processes, such as mitochondrial dysfunction, 27 meiotic disruption, and excess androgen production in follicular thecal cells, which may result in follicular atresia and anovulation. 11 Therefore, reducing body weight and improving insulin sensitivity are the key potential therapeutic approaches to address their metabolic, endocrine and reproductive health in these women. Multiple clinical studies consistently reported beneficial effects, such as improvement in menstrual cyclicity, insulin resistance, and ovulation rate post-weight loss, directing a better reproductive health in these women. 28 , 29 Irrespective of the beneficial effects, the adherence to the weight loss programs involving only lifestyle intervention is less, and often, dropout cases are high. 30 , 31 Further, lifestyle interventions alone are generally insufficient for managing long-term sustainable weight loss. 32 Therefore, pharmacotherapy combined with lifestyle intervention represents an alternative strategy to achieve weight loss. In women with obese and PCOS suffering from infertility, metformin remains the drug of choice, 33 while ongoing research is exploring the therapeutic potential of other insulin-sensitising agents such as roflumilast, dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide in the management of PCOS. In recent years, the use of anti-obesity medication has risen enormously among obese and PCOS women. Orlistat, naltrexone-bupropion, phentermine-topiramate, liraglutide, semaglutide, setmelanotide, and trizepatide are the present Food and Drug Administration (FDA) approved anti-obesity drugs. 34 Advances in understanding the neuroendocrine pathways regulating hunger and satiety have further accelerated the development of these therapies, with GLP-1 receptor agonists gaining increasing attention. Following its approval as an anti-diabetic drug by the US FDA in 2010, liraglutide was further endorsed as an anti-obesity drug in 2014, substantiated by its robust effectiveness in both glycaemic control and weight management. It is an acylated GLP-1 analogue, consisting of 31 amino acids and sharing 97% homology with endogenous GLP-1, with a half-life ranging from 11 to 15 hours, enabling once-daily subcutaneous dosing. 35 – 38 The primary action of the drug is regulating food intake by delaying gastric emptying, enhancing satiety, and regulating insulin and glucagon secretion from beta cells (β-cells) of the pancreas, while reducing hepatic glucose secretion, thereby contributing to weight management. 37 These functions are mediated by activating a G-protein, which subsequently elevates cyclic adenosine monophosphate (cAMP) levels and activates protein kinase A (PKA), initiating a signalling cascade, that leads to the opening of voltage-gated calcium channels and increases intracellular calcium levels, which further triggers the fusion of insulin-containing vesicles with the plasma membrane and promoting insulin secretion. 39 In long-term weight loss maintenance, it primarily drives sustainability by preserving leptin levels and increasing peptide YY (PYY), leading to an adaptive metabolic slowdown. 40 In addition to its effect on appetite suppression and weight management, it demonstrates a wide range of protective effects across various tissues and cell types, including central aspects of reproductive health such as the hypothalamic-pituitary-gonadal (HPG) axis and ovarian cells. These benefits are not restricted to a single target or organ but arise through interconnecting signalling pathways. Its mechanisms involve modulation of key regulators such as AMP-activated protein kinase (AMPK), phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt), wingless/integrated site (Wnt)/β-catenin, and autophagy-related pathways, allowing it to influence inflammation, oxidative stress, apoptosis, metabolism, and tissue remodelling in diverse biological contexts. 37 – 40 By targeting the central signalling cascades, liraglutide not only addresses metabolic outcomes but may also support reproductive function. 37 Clinical utility of liraglutide in managing metabolic dysregulation Liraglutide has been extensively investigated for its anti-diabetic, anti-obesity, and metabolic benefits. As summarised in Table 1 , clinical trials have demonstrated dose-dependent weight loss in obese and diabetic patients following subcutaneous administration. A dose-dependent weight loss was observed in subjects receiving liraglutide for 20 weeks at various doses, with a maximum reduction of 7.2 kg achieved at 3.0 mg, respectively, which notably outperforms the 2.8 kg observed in placebo and 4.1 kg with orlistat, a lipase inhibitor (120 mg, three times daily, orally), alongside an energy-deficient diet and physical activity. 41 While these results are promising, transient GI effects were more frequent in both liraglutide and orlistat compared to placebo. However, liraglutide was associated with a lower frequency of diarrhoea than orlistat and no events of acute pancreatitis were noted. The efficacy of the drug is further validated by a treatment with liraglutide (3 mg daily) for 56 weeks, which resulted in nearly triple weight reduction (8.4 ± 7.3 kg) compared to the placebo group (2.8 ± 6.5 kg), despite both groups receiving counselling for lifestyle modifications, underscoring the independent efficacy of the drug. It reduced fasting glucose, glycated haemoglobin (HbA1c), and fasting insulin levels and was associated with improved physical and mental health, thereby improving the healthy quality of life as compared to placebo. 42 Further long-term studies have demonstrated its beneficial effects in obese women, where 2.4 mg daily during year 1, followed by 3 mg daily in year 2, resulted in superior weight loss (7.8 kg) compared to placebo (2.0 kg) and orlistat (3.9 kg), indicating its better tolerability and sustained weight loss. 43 Beyond weight management and improvements in glycemic control, 12 months of liraglutide treatment has been shown to reduce visceral adiposity, improve insulin sensitivity and β cell function in metformin-treated obese patients with prediabetes compared to lifestyle modifications alone, with comparable weight loss of 7%. 44 – 46 Surprisingly, in these subjects, improved insulin sensitivity was observed as early as two weeks of treatment before achieving significant weight loss. Liraglutide significantly reduced major adverse cardiovascular events, cardiovascular mortality, and nephropathy risk in T2D patients with high cardiovascular risk. 47 – 50 (Supplementary Table 1 ). Table 1. Summarizes key clinical studies demonstrating the anti-obesity efficiency of liraglutide. Author Indicators Concentration of liraglutide Effect of liraglutide as an anti-obese drug Astrup et al. 41 double-blind, placebo-controlled trial Obese women 1.2, 1.8, 2.4, or 3.0 mg daily with lifestyle modifications for 20 weeks Weight loss was associated with reductions in waist circumference, systolic and diastolic blood pressure, as well as a decreased prevalence of metabolic syndrome and prediabetes. Astrup et al. 42 placebo-controlled trial 76% women with stable body weight, BMI ≥ 30 kg/m 2 and ≤ 40 kg/m 2 Continued with 40 dosage was 2.4 mg daily for 20-70 weeks and 3.0 mg daily for 70-96 weeks Superior weight loss was observed in the liraglutide group at both end points (year 1 and year 2) compared to placebo and orlistat. Decreased systolic blood pressure was accompanied by unchanged pulse rate. Mean FPG and HbA 1c levels were reduced, as well as improved lipid profiles. Inoue et al. 43 observational study T2D women 0.3-0.9 mg/day based on the tolerance for the drug for 2 years Long-term treatment improved glycemic control, improved lipid profile, and maintained body weight reduction. Pi-Sunyer et al. 44 double-blind, randomized controlled trial Obese women Scaled from 0.6 mg daily to 3 mg daily with lifestyle modification for 56 weeks When used as an adjuvant to increased physical activity and a reduced-calorie diet, it led to greater reductions in body weight, glycated hemoglobin, fasting glucose, and fasting insulin levels, along with improvements in insulin resistance and β-cell function. Santilli et al. 45 random trial longitudinal, randomized, controlled, parallel-arm study Obese T2D subjects Scaled from 0.6 to 1.8 mg daily for 3–12 months Even with the comparable weight loss in both the liraglutide and lifestyle intervention arms, pronounced visceral fat loss, and improvement in β-cell function were observed in the liraglutide arm. Mashayekhi et al. 46 double-blind and placebo-controlled study Obese men and women 1.8 mg/day liraglutide & 100 mg/day sitagliptin. The treatment period was 2 weeks and 14 weeks Liraglutide improved the HOMA-IR index even without significant weight loss, whereas the sitagliptin and hypocaloric diet group had no change. Mechanisms of liraglutide involved in managing metabolic and reproductive dysfunction Exploring the mechanisms involved in these beneficial clinical outcomes, liraglutide exerts its actions by modulating several key pathways, as summarized in Figure 2 , while supplementary Table 1 details the liraglutide- mediated mechanistic orchestration. One strategic way by which liraglutide drives anti-obesity effects is through modulation of fat metabolism and reduction of insulin resistance. Liraglutide upregulates brown fat differentiation, promoting thermogenesis in brown adipose tissue (BAT) via activation of soluble guanylyl cyclase (sGC)/cyclic guanosine phosphate (cGMP)/PKA signalling pathway. 51 This increases energy expenditure and heat production mediated by downregulation of miR-27b which facilitates the browning of white adipose tissue. 52 Tin addition, liraglutide upregulates adenylate cyclase 3 (AC3) 53 at both hepatic and serum levels, indicating a coordinated metabolic regulation. Figure 2. This schematic illustrates the diverse signaling pathway by which liraglutide modulates autophagy, fibrosis, inflammation, apoptosis, lipid accumulation, and cellular morphology & metabolism, exerting the protective effect across multiple organ systems. AC3: Adenylate Cyclase 3; AMPK: AMP-Activated Protein Kinase; AMPK-FOXO3: AMP-Activated Protein Kinase - Forkhead Box O3; AMPK-mTOR: AMP-Activated Protein Kinase - Mechanistic Target of Rapamycin; API3K: Phosphoinositide 3-Kinase; AP1: Activator Protein 1; cAMP: Cyclic Adenosine Monophosphate; cAMP/PKA/pCREB: Cyclic Adenosine Monophosphate/Protein Kinase A/phosphorylated cAMP Response Element-Binding Protein; CD36: Cluster of Differentiation 36; FGF21: Fibroblast Growth Factor 21; GSK3β: Glycogen Synthase Kinase 3 Beta; GLP-1R: Glucagon-Like Peptide-1 Receptor; JNK: c-Jun N-terminal Kinase; LKB1: Liver Kinase B1; MAPK: Mitogen-Activated Protein Kinase; miR-27b: microRNA-27b; mTOR: Mechanistic Target of Rapamycin; MYD88: Myeloid Differentiation Primary Response 88; NFkB: Nuclear Factor kappa-light-chain-enhancer of activated B cells; NLPR3: NOD-, LRR- and pyrin domain-containing protein 3; PKA: Protein Kinase A; PI3K: Phosphoinositide 3-Kinase; pCREB: phosphorylated cAMP Response Element-Binding Protein; RAGE: Receptor for Advanced Glycation End-products; SGC: Soluble Guanylate Cyclase; Survinin: Baculoviral IAP Repeat-Containing Protein 5; TFEB: Transcription Factor EB; TLR4: Toll-Like Receptor 4; Wnt: Wingless/Integrated; β-catenin: Beta-catenin. Liraglutide suppresses gluconeogenic enzymes such as glucose-6-phosphatase and phosphoenolpyruvate carboxykinase via the Wnt/β-catenin pathway, while enhancing expression of glucose transporter type 4 (GLUT4) in both liver and skeletal muscle. 54 , 55 It also augments glycolysis and glycogenesis via activation of hexokinase and pyruvate kinase while preserving pancreatic β-cell mass by inhibiting apoptosis through the cAMP-PI3K pathway and increasing proliferation through reducing oxidative stress. 56 , 57 It activates autophagy via AMPK and transcription factor EB (TFEB), promoting lysosomal biogenesis and lipid clearance, thus preventing hepatic lipid accumulation. 58 , 59 In adipose tissue, it activates fibroblast growth factor 21 (FGF21)/liver kinase B1(LKB1)/AMPK/acetyl-CoA carboxylase 1 (ACC1) axis, thus reducing lipogenesis, promoting fatty acid oxidation, and suppressing pro-inflammatory signalling. 60 It also reduces β-site amyloid precursor protein cleaving enzyme 1 (BACE1) activity, thereby exhibiting a neuroprotective action. 61 Higher leptin levels observed in both PCOS and obese conditions inhibit follicular growth as well as hinder oocyte maturation. 62 Liraglutide in obese mice combats impaired leptin signalling through the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2-STAT3) signalling pathway, lowers expression of improves insulin resistance, lowers fasting insulin levels, decreases hyperandrogenism, and improves menstrual cyclicity pattern, thereby creating a favourable environment relevant to improving reproductive health. 63 – 68 Liraglutide demonstrates strong anti-inflammatory activity in PCOS and obese conditions. In human chondrocytes, it inhibits nuclear factor κB (NF-κB)/tumour necrosis factor-alpha (TNF-α) signalling pathway, thereby attenuating extracellular matrix (ECM) proteins degradation and advanced glycation end products (AGE)-induced apoptosis. 69 Similarly, in fibroblasts, liraglutide attenuates collagen overproduction by modulating the cluster of differentiation 36 (CD36)/c-Jun N-terminal kinase (JNK)/activator protein 1 (AP1) pathway. 70 In addition, it suppresses Wnt/β-catenin and Toll-Like Receptor 4 (TLR4)/myeloid differentiation primary response 88 (MyD88)/NF-κB inflammatory cascade to reduce ECM deposition and pro-inflammatory cytokine expression. 71 , 72 It also reduces sclerosis and autophagy in renal cells, 73 while in the vasculature, it reduces inflammatory marker expression in obese conditions. 74 Further, it enhances bone mineral density and decreases bone resorption, thereby protecting against osteoporosis. 75 Its neuroprotective effects have also been reported, with improved neuronal cell survival and repair via cAMP/PKA,CREB and Wnt signalling pathways. 76 – 79 In spinal cord and hypoxic ischemic injuries, it preserves tissue integrity by activation of AMPK/Forkhead Box O3 (FOXO3) mediated autophagy and PI3K/Akt/glycogen synthase kinase 3 β (GSK3β) signalling, respectively. 80 , 81 It reverses synaptic loss and memory impairment, improves cognition and motor coordination. 82 – 84 While these multi-organ effects range from neuroprotection to bone remodelling, highlighting the systemic versatility of liraglutide, they serve as parallel evidence of liraglutide’s ability to conserve and restore cellular homeostasis. The anti-inflammatory profile of liraglutide is very relevant, and it lowers the level of C-X-C motif chemokine ligand 10 (CXCL10) by blocking the JAK signalling pathway in PCOS condition. 85 , 86 It also exhibits potent anti-inflammatory effects by inhibiting the NF-kB and TNF-α pathways, accompanied by upregulation of sirtuin 1 (SIRT1) and increased phosphorylation of insulin receptor substrate (IRS-1). 87 – 89 Furthermore, the beneficial effect of liraglutide on decreased inflammation is by lowering key proinflammatory markers, including interleukin-6 (IL-6), interleukin-1beta (IL-1β), and chemokine C-C motif ligand 2 (CCl2). 90 Overall, liraglutide highlights the anti-inflammatory effects at both systemic and organ levels, balancing the inflammatory milieu. 91 – 94 However, it also warrants further investigation into its effects on ovarian oxidative stress and granulosa cell survival to optimize the use of the drug in correcting reproductive dysfunction in obesity and PCOS conditions. Liraglutide alters the overall diversity and abundance of gut microbiota, elevates well-known probiotics, 95 , 96 promotes bacteria-derived butyrate production and improves lipid profile, inducing weight reduction, regulates glucose metabolism, and reduces insulin resistance and hyperandrogenism, ultimately promoting better metabolic health in obese, PCOS, and diabetic condition. 97 – 103 Its effect is mediated by enrichment of the phylum Bacillota, leading to a reduced Bacilliota to Bacteroidota ratio, which is usually lower in the PCOS condition. 104 – 106 Clinical trials involving liraglutide have been linked to improved ovarian morphology and function, as well as the restoration of regular menstrual cyclicity. 68 These improvements are likely mediated through modulating gut microbiota, which in turn influences hormonal balance and systemic inflammation. However, further clinical trials are warranted to confirm the therapeutic effects of liraglutide. One of the promising strategies of liraglutide in improving reproductive health is hormone profile modification by interconnected metabolic and endocrine modifications ( Figure 3 ). Hyperinsulinemia and elevated LH secretion in obese and PCOS are the key mediators of ovarian-associated hyperandrogenism. Liraglutide reduces adipose tissue inflammation and lipotoxicity and thereby decreases hyperinsulinemia and improves insulin sensitivity, 107 which in turn reduces androgen synthesis by following the PI3K pathway mediated CYP17 driven androgen synthesis activity. 108 It also improves insulin resistance and elevates SHBG, thereby reducing androgen levels and resulting in a lowered free androgen index. 109 – 112 Furthermore, anti-mullerian hormone (AMH) produced by granulosa cells stimulates the pulsatile release of gonadotropin-releasing hormone (GnRH) and downstream gonadotrophins (LH and FSH), which are closely associated with the maintenance of ovarian reserve and function. Notably, AMH levels are often elevated in obese women with PCOS. 113 , 114 Marking all the positive alterations in terms of improving the hormonal index, thereby supporting folliculogenesis, liraglutide may be a useful treatment choice for women undergoing PCOS & obesity ( Figure 3 ). Figure 3. Effect of liraglutide in improving ovarian health explains the mechanism of liraglutide in improving folliculogenesis through various mechanisms (created with BioRender.com ). It regulates GnRH pulsatile, FSH and LH level through HPO axis, reduces proinflammatory cytokines, and regulates steroid hormone production thereby affecting ovarian function. At follicle level, It also improves GJA1 protein homeostasis between oocytes and granulosa cells, supporting the effective cellular communication, improves granulosa cell survival by reducing FOXO1 expression, reduces the proinflammatory cytokines in the follicular fluid, reduces the methylation of the leptin promoter in granulosa cells, promoting the improvement in follicular development and ovulation, aiding the improved natural pregnancy rates. (Black upward arrow: increases; black downward arrow: decreases;). CXCL10: C-X-C motif chemokine ligand 10; FSH: Follicle stimulating hormone; FoxO1: Forkhead box protein O1; GJA1: Gap junction protein 1; GnRH: Gonadotropin-releasing hormone; GLP-1: Glucagon-like peptide-1; HPO: Hypothalamus-pituitary-ovary; JAK2: Janus kinase 2; LH: Luteinizing hormone; NF-kB: Nuclear factor kappa-light-chain-enhancer of activated B cells; PCOS: Polycystic ovary syndrome; SHBG: sex hormone-binding globulin; STAT3: signal transducer and activator of transcription 3; TNF-α: Tumor Necrosis Factor alpha; Wnt/β-catenin signaling: Wingless-related integration site/beta-catenin signaling. In addition, liraglutide reduced methylation of the leptin promoter in ovarian granulosa cells in PCOS conditions, which was positively connected to higher ovulation rates, better hormonal profiles, and spontaneous conception. 115 However, the translational impact of the findings is constrained by the small sample size and retrospective design, which limits the generalizability. It alters the phosphorylation status of FoxO1, a known negative regulator of cell survival, by promoting Akt-mediated phosphorylation. This leads to reduced expression of pro-apoptotic genes Bim and FasL, decreases apoptosis of granulosa cells, and thereby improves folliculogenesis. 116 Liraglutide restores the interaction between granulosa cells and oocytes, which is essential for oocyte growth, by improving the expression of the gap junction protein alpha 1 (GJA1) 86 and ferredoxin 1 (FDX1), the latter being critical for p450 enzyme activation in PCOS conditions. 117 It also reversed PCOS-induced downregulation of steroidogenic enzymes, namely cholesterol side-chain cleavage enzyme (CYP11A1) and aromatase (CYP19A1) and impaired follicular development. The restoration of these enzymes led to improved estradiol synthesis, folliculogenesis and overall reproductive health. These beneficial effects of liraglutide are further driven by its potential anti-inflammatory effect, which favourably enables the ovarian microenvironment for promoting folliculogenesis and ovulation. Collectively, these beneficial effects position liraglutide as a potential therapeutic option for improving follicular growth in PCOS. Recent studies have underlined several specific mechanisms through which liraglutide improves ovarian health by supporting follicular development ( Figure 2 ). Liraglutide reduced methylation of the LEP (leptin) promoter in ovarian granulosa cells in PCOS conditions, 114 which positively connected to higher ovulation rates, better hormonal profiles, and spontaneous conception. It alters the phosphorylation status of forkhead box protein O1 (FoxO1), a known negative regulator of cell survival, by promoting Akt-mediated phosphorylation, resulting in reduced expression of pro-apoptotic genes such as Bim and FasL, resulting in decreased apoptosis of granulosa cells and improved folliculogenesis. 115 The administration of Liraglutide restores the equilibrium between granulosa cells and oocytes by improving the expression of the gap junction protein alpha 1 (GJA1) in PCOS conditions through the JAK) signaling pathway. 86 Importantly, it upregulated Ferredoxin 1 (FDX1) expression in PCOS condition, a protein critical for p450 enzyme activation, which is suppressed in this condition. 116 It also reversed PCOS-induced downregulation of steroidogenic enzymes namely cholesterol side-chain cleavage enzyme (CYP11A1) and aromatase (CYP19A1) and impaired follicular development. The restoration of these enzymes led to improved estradiol synthesis, folliculogenesis and overall reproductive health. These beneficial effects liraglutide are further driven by its potential anti-inflammatory effect, which favorably enables the ovarian microenvironment for promoting folliculogenesis and ovulation. The dual function of liraglutide, in increasing granulosa cell survival and reducing inflammation, makes it a potential therapeutic option for improving follicular growth in PCOS conditions. Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women While the mechanistic plausibility of liraglutide in preclinical models is robust, the clinical validation in PCOS/obese population remains a landscape of promise, and available evidence is contingent on methodological heterogeneity. Liraglutide has demonstrated promising effects in improving metabolic and reproductive parameters in non-diabetic women with obesity and PCOS ( Table 2 ). A randomized, placebo-controlled phase 3 clinical trial involving 82 obese and PCOS patients reported a significant weight reduction in the liraglutide group, compared to the placebo group, leading to regular menstrual cyclicity with two participants achieved spontaneous conception. 67 Effects like lowered testosterone, improved insulin resistance, improved lipid profile and adiposity, improved menstrual cyclicity with one participant achieving pregnancy and delivering a healthy child were pronounced in an extreme case of PCOS with endocrine disorder depicted by HAIR-AN syndrome. Interestingly, these benefits occurred with minimal weight loss following post-liraglutide treatment in these patients underscoring its pharmacologic effects independent of weight reduction. 68 In a study involving 72 overweight women with PCOS, liraglutide led to reduction in body weight. Increase in SHBG level and decrease in free testosterone level. Although it did not improve insulin sensitivity, reductions in fasting glucose and leptin levels were observed. This study did not elaborate on reproductive functions as well as hormone levels. 109 Furthermore, in a cohort of 30 obese PCOS patients, liraglutide was superior to metformin in improving glucose metabolism, lipid profiles, and BMI, as well as reducing leptin promoter methylation in granulosa cells, thereby increasing leptin secretion in these cells. Moreover, significant reductions in FSH, LH, and E2 levels were observed after liraglutide intervention, alongside improved menstrual regularity, ovulation rates, and natural pregnancy occurrences. 110 However, this study lacked a placebo group, had a small sample size. In another study involving obese women with PCOS, liraglutide treatment resulted in greatest weight loss, followed by roflumilast and metformin, with metformin showing the least among the three treatment groups. All three treatment groups experienced improvements in menstrual regularity. However, roflumilast had a significant upper hand over the liraglutide arm. No significant intergroup differences in free testosterone, SHBG, androstenedione, dehydroepiandrosterone (DHEA), FSH, and LH were observed. In addition, improved glucose homeostasis was found in liraglutide patients compared to metformin and roflumilast subjects. However, this study had a few limitations, including a small sample size, short duration, open-label nature of the study, and lack of active lifestyle promotion. 117 In contrast, placebo-controlled, randomized trial involving 65 overweight PCOS women treated with liraglutide for 26 weeks showed average weight loss, improved fasting glucose, improved insulin sensitivity, menstrual regularity and normalization of AMH level. Further, three-dimensional ultrasound revealed a decrease in both total ovarian volume and stromal volume. However, this study also had a limitation of participant selection bias, as partial recruitment was by social media, and lifestyle changes were not actively promoted throughout the study. 118 Among the Chinese population, the combination therapy of metformin and liraglutide has proved its efficacy in weight loss and improving hyperandrogenemia, including total testosterone, free androgen index, and SHBG levels and showed a menstrual cycle recovery rate of 92.59%, whereas the metformin alone group showed 88% recovery rate. 110 Nevertheless, limitations included the absence of a control group, potential selection bias, lack of fertility outcome data, short follow-up duration, and their small sample size, single-center design. In addition, this study did not assess key reproductive parameters such as ovulation or pregnancy outcomes. Table 2. Clinical evidence of liraglutide alone or in combination with metformin improving in reproductive, metabolic, and endocrine dysfunction in obese and PCOS women. Author, study & design Population Dosage & treatment duration of liraglutide Effect of liraglutide on metabolic, endocrine, reproductive changes Elkind-Hirsch et al. 67 Double-blind RCT Obese, PCOS women Liraglutide 3 mg/day vs. placebo + lifestyle, for 32 weeks. Decreased weight, and increased insulin sensitivity. Improved endocrine and metabolic markers over placebo. More regular menstrual cyclicity and out of 44 patients, 2 pregnancies, healthy births. Livadas et al. 68 Case Study HAIR-AN syndrome/PCOS women Liraglutide 1.8 mg/day, for 14 months. Decrease of insulin resistance, androgen levels, with improvement of fat deposition. More regular menstrual cyclicity and out of 5 patients, 1 pregnancy, live birth. Jensterle et al. 117 Prospective RCT Obese, PCOS women Liraglutide 1.2 mg QD, s.c. vs. metformin 1000 mg BID or roflumilast 500 μg, QD, 12 weeks. No significant change in hyperandrogenism. Increased menstrual frequency outperformed metformin in reproductive parameters. Nylander et al. 118 Double-blind RCT Overweight PCOS women Liraglutide 1.8 mg vs. placebo, 26 weeks follow-up. Effective weight loss, decreased fasting glucose, hemoglobin A1c, increased SHBG, and decreased free testosterone. Decreased ovarian and stromal volume, and more regular menstrual cyclicity. Xing et al. 110 Prospective, Open-label RCT PCOS women Metformin 1000 mg BID or liraglutide 1.2 mg QD, s.c. + metformin for 12 weeks. In combination with metformin, it improved bodyweight, fasting glucose, hyperandrogenism, and sex hormone balance. Recovery rate of the menstrual cycle was better than metformin group in the combination group. Jensterle et al. 121 Open-label RCT Obese, PCOS women Liraglutide 1.2 mg QD vs. metformin + liraglutide for 12 weeks. In combination with metformin Increased glucose metabolism, decreased BMI, decreased androstenedione, and greater improvements in ovarian morphology and metabolism. Long et al. 122 Retrospective Obese, PCOS women Liraglutide 0.6 mg QD + metformin 0.85 g BID for 12 weeks. In combination with metformin, it improved lipid metabolism, insulin sensitivity, decreased free androgen index better then when metformin given alone. Reproductive functions not assessed. Salamun et al. 123 Prospective RCT Infertile, obese PCOS women Metformin1000 mg BID vs. metformin + liraglutide 1.2 mg QD for 12 weeks. In combination with metformin, it decreased fasting glucose, OGTT, HOMA-IR, decreased LH & testosterone, improved metabolic and endocrine outcomes. Increased pregnancy rate per embryo transfer (85.7% in combination with metformin). Adding on, the combination of liraglutide with metformin, appears to offer synergistic benefits on metabolic and reproductive outcomes in obese women with PCOS. Combination of liraglutide and metformin not only offers superior glycemic control more effectivly but also provides a significant advantage in promoting body weight loss, emphasizing its role in metabolic regulation in comparison to placebo, sitagliptin, glimepiride, dulaglutide, insulin glargine, and NPH insulin. 119 , 120 Importantly, the combined treatment did not increase the risk of hypoglycemia but induced a higher incidence of adverse effects of gastrointestinal disturbances, such as nausea, compared to metformin. However, the severity of these adverse effects was reduced over time. 121 Nevertheless, limitations included the absence of a control group, potential selection bias, lack of fertility outcome data, short follow-up duration and their small sample size, single-center design. 122 Few studies did not assess key reproductive parameters such as ovulation, menstrual cyclicity, or pregnancy outcomes. Subsequently infertile obese PCOS patients treated either with metformin in combination with low-dose liraglutide, resulting in markedly higher pregnancy rates per embryo transfer in the liraglutide despite similar reductions in weight and visceral adiposity. 123 Higher cumulative pregnancy rates are supported by improved menstrual cycle regularity, glucose metabolism, and modulation of LH and progesterone levels. These findings suggest liraglutide or in combination with metfromin is effective for weight reduction and regulated hormonal balance in women with obesity and PCOS, which supports its potential as a therapeutic option that may exert beneficial effects on reproductive outcomes in women with metabolic disorders, providing a potential therapeutic option for addressing infertility in this population. Discussion Liraglutide, the foremost GLP-1 R agonist, has emerged as pivotal in the dual management of obesity and diabetes. It seeks more attention due to its rise in global consumption, potentially enabling a more holistic and comprehensive treatment approach. Notably, along with clinical triumphs of successful weight loss and adipokine rebalancing, liraglutide reshapes its therapeutic horizon, directing towards synced treatment for reproductive dysfunction. Liraglutide has demonstrated its multifaceted effects in the PCOS murine model, indicating the rescue of folliculogenesis, 86 improvement of granulosa cell proliferation, 114 which are crucial for balanced steroidogenesis, and alleviation of a proinflammatory environment. Crucially, clinical trials have reinforced the effectiveness of the drug, which significantly improved both pregnancy rates in combination with metformin and successful embryo transfer. 124 Comparatively, metformin has long served as the most widely used pharmacological therapy in PCOS due to its insulin-sensitizing effects, affordability, and extensive clinical experience. In contrast, liraglutide promotes weight reduction primarily through appetite regulation, delayed gastric emptying, and enhanced satiety signaling. As a result, liraglutide often produces greater weight loss and improvements in metabolic parameters compared with metformin monotherapy. These differences suggest that GLP-1 receptor agonists may occupy an important position as adjunctive therapy, particularly in individuals who do not achieve adequate metabolic control with lifestyle modification and insulin sensitizers alone. However, a dose-dependent weight loss was observed in subjects receiving liraglutide, which was found to be better than orlistat. While these results are promising, transient GI effects such as nausea, vomiting, headache, diarrhoea, constipation, and injection site reactions, and the non-occurrence of pregnancy led to 18% dropout rate among the patients. The other limitations included were short trial duration, lack of ovulation or live birth assessment, and absence of clinical evaluation of hirsutism. 41 , 67 However, no events of acute pancreatitis were observed, as seen in other GLP-1 Ras. In addition to these, the other limitations noted were the absence of a control group, potential selection bias, short follow-up duration, small sample size, single-centre design and did not assess key reproductive parameters such as ovulation or pregnancy outcomes. 110 , 118 Beyond these short-term adverse effects, the reproductive safety of liraglutide is questionable and hence recommended to discontinue before planned conception, due to limited human data regarding pregnancy outcomes. Current evidence suggests favourable metabolic effects; the long-term endocrine consequences of the sustained effect of liraglutide in reproductive-age women remain incompletely understood. Continued pharmacovigilance and longitudinal studies are therefore necessary to clarify these aspects. Liraglutide encapsulated tannic acid and aluminium ion nanoparticles have proved durable and painless with long-term therapeutic efficacy. Efforts in this direction have further led to exploring the oral route of intake. Prolonged release of liraglutide by chitosan nanoparticles, and protection of liraglutide from degradation by gastric and intestinal fluid has shed a ray of hope. 125 – 128 The right mode of administration also may reduce the side effects, like gastrointestinal reactions, traditionally observed in liraglutide dosage. 129 , 130 Further studies are required in the direction of providing an affordable generic version of liraglutide, evaluating the long-term durability of the reproductive benefit, and identifying biomarkers that could also pave the way for personalised therapy in improving fertility, as well as tailored dosage. Conclusion Liraglutide is a crucial addition to the therapeutic options for women with PCOS-related metabolic and reproductive dysfunction. Evidence from randomized controlled trials and retrospective studies highlights the efficacy of liraglutide in modulating hormone levels and improving insulin sensitivity, which may contribute to regular menstrual cyclicity. Notably, a limited number of studies have further investigated liraglutide’s direct impact on reproductive success by assessing and demonstrating increased natural pregnancy rates and responses to ART. However, these findings remain preliminary. Despite these successes and advancements, critical limitations to consider include brief intervention durations, small sample sizes, lack of ovulation tracking, cost of treatment and limited longitudinal follow-up of live birth data. Furthermore, important considerations such as treatment accessibility and uncertainties regarding reproductive safety must be carefully weighed when considering liraglutide for women of reproductive age. Future research should focus on exploring the biochemical mechanisms underlying liraglutide’s long-term effects on reproductive health through improvements in weight and insulin sensitivity, rather than as a definitive fertility therapy. By embracing cutting-edge treatments like liraglutide, we can better address the complex challenges of infertility and empower women on their journey to reproductive health. Additionally, further research in this area will enhance the lives of women facing these challenges and lead to improved clinical outcomes. The findings underscore the importance of individualised treatment strategies in addressing the intricate issues of PCOS and obesity-related infertility. At present, liraglutide should be viewed primarily as a metabolic therapy that may indirectly support reproductive health through improvements in weight and insulin sensitivity rather than as a definitive fertility treatment. Ethical approval Ethical approval and consent were not required. Data availability statement The data availability statement for this study has been duly registered and archived in the Biostudies repository, which is recognized for its commitment to the accessibility and preservation of scientific data. The extended data ( Supplementary Table 1) supported by this study is publicly available and can be accessed at the following DOI link: https://doi.org/10.6019/S-BSST2135 . 131 Data are available under the terms of the CC0 1.0 Universal. Acknowledgments The authors acknowledge the use of BioRender.com for the creation of Figure 2 . References 1. Jin X, Qiu T, Li L, et al. : Pathophysiology of obesity and its associated diseases. Acta Pharm. Sin. B. 2023; 13 (6): 2403–2424. PubMed Abstract | Publisher Full Text | Free Full Text 2. Chaudhary M, Sharma P: Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019-2021) data. Lancet. Reg. Health. Southeast Asia. 2023; 14 : 100208. PubMed Abstract | Publisher Full Text | Free Full Text 3. Jung UJ, Choi MS: Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int. J. Mol. Sci. 2014; 15 (4): 6184–6223. PubMed Abstract | Publisher Full Text | Free Full Text 4. Lonardo MS, Cacciapuoti N, Guida B, et al. : Hypothalamic-ovarian axis and adiposity relationship in polycystic ovary syndrome: physiopathology and therapeutic options for the management of metabolic and inflammatory aspects. Curr. Obes. Rep. 2024; 13 (1): 51–70. PubMed Abstract | Publisher Full Text | Free Full Text 5. Sanchez-Garrido MA, Tena-Sempere M: Metabolic dysfunction in polycystic ovary syndrome: Pathogenic role of androgen excess and potential therapeutic strategies. Mol. Metab. 2020; 35 : 100937. PubMed Abstract | Publisher Full Text | Free Full Text 6. Su P, Chen C, Sun Y: Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. J. Ovarian Res. 2025; 18 (1): 34. PubMed Abstract | Publisher Full Text | Free Full Text 7. Kim JJ: Obesity and Polycystic Ovary Syndrome. J. Obes. Metab. Syndr. 2024; 33 (4): 289–301. PubMed Abstract | Publisher Full Text | Free Full Text 8. Silvestris E, de Pergola G , Rosania R, et al. : Obesity as disruptor of the female fertility. Reprod. Biol. Endocrinol. 2018; 16 (1): 22. PubMed Abstract | Publisher Full Text | Free Full Text 9. Teede H, Deeks A, Moran L: Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010; 8 : 41. PubMed Abstract | Publisher Full Text | Free Full Text 10. Zheng L, Yang L, Guo Z, et al. : Obesity and its impact on female reproductive health: unraveling the connections. Front. Endocrinol. (Lausanne). 2024; 14 : 1326546. PubMed Abstract | Publisher Full Text | Free Full Text 11. Dağ ZÖ, Dilbaz B: Impact of obesity on infertility in women. J. Turk. Ger. Gynecol. Assoc. 2015; 16 (2): 111–117. PubMed Abstract | Publisher Full Text | Free Full Text 12. Best D, Avenell A, Bhattacharya S: How effective are weight-loss interventions for improving fertility in women and men who are overweight or obese? A systematic review and meta-analysis of the evidence. Hum. Reprod. Update. 2017; 23 (6): 681–705. Publisher Full Text 13. Bray GA, Ryan DH: Evidence-based weight loss interventions: individualized treatment options to maximize patient outcomes. Diabetes. Obes. Metab. 2021; 23 Suppl 1 : 50–62. PubMed Abstract | Publisher Full Text 14. Pavli P, Triantafyllidou O, Kapantais E, et al. : Infertility improvement after medical weight loss in women and men: a review of the literature. Int. J. Mol. Sci. 2024; 25 (3): 1909. PubMed Abstract | Publisher Full Text | Free Full Text 15. Drucker DJ: Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018; 27 (4): 740–756. Publisher Full Text 16. Khan D, Ojo OO, Woodward OR, et al. : Evidence for involvement of GIP and GLP-1 receptors and the gut-gonadal axis in regulating female reproductive function in mice. Biomolecules. 2022; 12 (12): 1736. PubMed Abstract | Publisher Full Text | Free Full Text 17. Vrbikova J, Hainer V: Obesity and polycystic ovary syndrome. Obes. Facts. 2009; 2 (1): 26–35. PubMed Abstract | Publisher Full Text | Free Full Text 18. Purwar A, Nagpure S: Insulin resistance in polycystic ovarian syndrome. Cureus. 2022; 14 (10): e30351. PubMed Abstract | Publisher Full Text | Free Full Text 19. Rojas J, Chávez M, Olivar L, et al. : Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int. J. Reprod. Med. 2014; 2014 : 719050. PubMed Abstract | Publisher Full Text | Free Full Text 20. Ding H, Zhang J, Zhang F, et al. : Resistance to the insulin and elevated level of androgen: a major cause of polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 2021; 12 : 741764. PubMed Abstract | Publisher Full Text | Free Full Text 21. Nestler JE, Powers LP, Matt DW, et al. : A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 1991; 72 (1): 83–89. PubMed Abstract | Publisher Full Text 22. Baptiste CG, Battista MC, Trottier A, et al. : Insulin and hyperandrogenism in women with polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 2010; 122 (1-3): 42–52. PubMed Abstract | Publisher Full Text | Free Full Text 23. Bril F, Ezeh U, Amiri M, et al. : Adipose tissue dysfunction in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2023; 109 (1): 10–24. PubMed Abstract | Publisher Full Text | Free Full Text 24. Ghafoor S: Impact of obesity and weight management on women with polycystic ovary syndrome and coexisting obesity – a brief narrative review. Acta Pharm. Sin. B. 2023; 13 (6): 2403–2424. PubMed Abstract | Publisher Full Text | Free Full Text 25. Hajam YA, Rather HA, Neelam, et al. : A review on critical appraisal and pathogenesis of polycystic ovarian syndrome. Endocr. Metab. Sci. 2024; 14 : 100162. Publisher Full Text 26. Van der Spuy ZM, Dyer SJ: The pathogenesis of infertility and early pregnancy loss in polycystic ovary syndrome. Best Pract. Res. Clin. Obstet. Gynaecol. 2004; 18 (5): 755–771. Publisher Full Text 27. Das M, Sauceda C, Webster NJG: Mitochondrial dysfunction in obesity and reproduction. Endocrinology. 2020; 162 (1): bqaa158. PubMed Abstract | Publisher Full Text | Free Full Text 28. Cowan S, Lim S, Alycia C, et al. : Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr. Disord. 2023; 23 : 14. PubMed Abstract | Publisher Full Text | Free Full Text 29. Rodrigo N, Chen H, Pollock CA, et al. : Preconception weight loss improves fertility and maternal outcomes in obese mice. J. Endocrinol. 2022; 253 (1): 27–38. PubMed Abstract | Publisher Full Text 30. Colombo O, Ferretti VV, Ferraris C, et al. : Is drop-out from obesity treatment a predictable and preventable event? Nutr. J. 2014; 13 : 13. PubMed Abstract | Publisher Full Text | Free Full Text 31. Lemstra M, Bird Y, Nwankwo C, et al. : Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer. Adherence. 2016; 10 : 1547–1559. PubMed Abstract | Publisher Full Text | Free Full Text 32. Foster G: The behavioral approach to treating obesity. Am. Heart J. 2006; 151 (3): 625–627. Publisher Full Text 33. Attia GM, Almouteri MM, Alnakhli, et al. : Role of metformin in polycystic ovary syndrome (PCOS)-related infertility. Cureus. 2023; 15 (8): e44493. PubMed Abstract | Publisher Full Text | Free Full Text 34. Müller TD, Blüher M, Tschöp MH, et al. : Anti-obesity drug discovery: advances and challenges. Nat. Rev. Drug Discov. 2022; 21 (3): 201–223. PubMed Abstract | Publisher Full Text | Free Full Text 35. Knudsen LB, Lau J: The discovery and development of liraglutide and semaglutide. Front. Endocrinol (Lausanne). 2019; 10 : 155. PubMed Abstract | Publisher Full Text | Free Full Text 36. Mehta A, Marso SP, Neeland IJ, et al. : Liraglutide for weight management: a critical review of the evidence. Obes. Sci. Pract. 2016; 3 (1): 3–14. PubMed Abstract | Publisher Full Text | Free Full Text 37. Müller TD, Finan B, Bloom SR, et al. : Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019; 30 : 72–130. PubMed Abstract | Publisher Full Text | Free Full Text 38. Campbell JE, Drucker DJ: Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17 (6): 819–837. Publisher Full Text 39. Verspohl EJ: Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 2009; 124 (1): 113–138. PubMed Abstract | Publisher Full Text 40. Secher A, Jelsing J, Baquero AF, et al. : The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J. Clin. Invest. 2014; 124 (10): 4473–4488. PubMed Abstract | Publisher Full Text | Free Full Text 41. Astrup A, Rössner S, Van Gaal L, et al. : Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009; 374 (9701): 1606–1616. Publisher Full Text 42. Astrup A, Carraro R, Finer N, et al. : Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. 2012; 36 (6): 843–854. PubMed Abstract | Publisher Full Text | Free Full Text 43. Inoue K, Maeda N, Fujishima Y, et al. : Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: An observational study. Diabetol. Metab. Syndr. 2014; 6 : 95. PubMed Abstract | Publisher Full Text | Free Full Text 44. Pi-Sunyer X, Astrup A, Fujioka K, et al. : A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015; 373 (1): 11–22. Publisher Full Text 45. Santilli F, Simeone PG, Guagnano MT, et al. : Effects of liraglutide on weight loss, fat distribution, and β-cell function in obese subjects with prediabetes or early type 2 diabetes. Diabetes Care. 2017; 40 (11): 1556–1564. Publisher Full Text 46. Mashayekhi M, Nian H, Mayfield D, et al. : Weight loss-independent effect of liraglutide on insulin sensitivity in individuals with obesity and prediabetes. Diabetes. 2024; 73 (1): 38–50. PubMed Abstract | Publisher Full Text | Free Full Text 47. Marso SP, Daniels GH, Brown-Frandsen K, et al. : Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 2016; 375 (4): 311–322. PubMed Abstract | Publisher Full Text | Free Full Text 48. Verma S, Poulter NR, Bhatt DL, et al. : Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018; 138 (25): 2884–2894. Publisher Full Text 49. Mann JFE, Fonseca V, Mosenzon O, et al. : Response by Mann et al to Letter regarding article, “Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease: results from the LEADER trial”. Circulation. 2019; 139 (22): e1017–e1018. PubMed Abstract | Publisher Full Text 50. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. : Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 2017; 377 (9): 839–848. Publisher Full Text 51. Zhu E, Yang Y, Zhang J, et al. : Liraglutide suppresses obesity and induces brown fat-like phenotype via soluble guanylyl cyclase mediated pathway in vivo and in vitro. Oncotarget. 2016; 7 (49): 81077–81089. PubMed Abstract | Publisher Full Text | Free Full Text 52. Wang X, Chen S, Lv D, et al. : Liraglutide suppresses obesity and promotes browning of white fat via miR-27b in vivo and in vitro. J. Int. Med. Res. 2021; 49 (11): 03000605211055059. PubMed Abstract | Publisher Full Text | Free Full Text 53. Li Z, Liang Y, Xia N, et al. : Liraglutide reduces body weight by upregulation of adenylate cyclase 3. Nutr. Diabetes. 2017; 7 (5): e265. PubMed Abstract | Publisher Full Text | Free Full Text 54. Qin Y, Chen M, Yang Y, et al. : Liraglutide improves hepatic insulin resistance via the canonical Wnt signaling pathway. Mol. Med. Rep. 2018; 17 (5): 7372–7380. PubMed Abstract | Publisher Full Text 55. Chen LN, Lyu J, Yang XF, et al. : Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice. Int. J. Mol. Med. 2013; 32 (4): 892–900. PubMed Abstract | Publisher Full Text 56. Bregenholt S, Møldrup A, Blume N, et al. : The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem. Biophys. Res. Commun. 2005; 330 (2): 577–584. PubMed Abstract | Publisher Full Text 57. Tamura K, Minami K, Kudo M, et al. : Liraglutide improves pancreatic beta cell mass and function in alloxan-induced diabetic mice. PLoS One. 2015; 10 (5): e0126003. PubMed Abstract | Publisher Full Text | Free Full Text 58. Fang Y, Ji L, Zhu C, et al. : Liraglutide alleviates hepatic steatosis by activating the TFEB-regulated autophagy-lysosomal pathway. Front. Cell Dev. Biol. 2020; 8 : 602574. PubMed Abstract | Publisher Full Text | Free Full Text 59. He Y, Ao N, Yang J, et al. : The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy. Ann. Hepatol. 2020; 19 (1): 44–52. PubMed Abstract | Publisher Full Text 60. Zhang N, Liu C, Zhang Y, et al. : Liraglutide regulates lipid metabolism via FGF21-LKB1-AMPK-ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice. Biochem. Biophys. Res. Commun. 2021; 548 : 120–126. PubMed Abstract | Publisher Full Text 61. Jantrapirom S, Nimlamool W, Chattipakorn N, et al. : Liraglutide suppresses tau hyperphosphorylation, amyloid beta accumulation through regulating neuronal insulin signaling and BACE-1 activity. Int. J. Mol. Sci. 2020; 21 (5): 1725. PubMed Abstract | Publisher Full Text | Free Full Text 62. Paz-Filho G, Mastronardi C, Wong ML, et al. : Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian. J. Endocrinol. Metab. 2012; 16 (Suppl 3): 549–555. PubMed Abstract | Publisher Full Text | Free Full Text 63. Childs GV, Odle AK, MacNicol MC, et al. : The importance of leptin to reproduction. Endocrinology. 2020; 162 (2): bqaa204. PubMed Abstract | Publisher Full Text | Free Full Text 64. Brannian JD, Hansen KA: Leptin and ovarian folliculogenesis: implications for ovulation induction and ART outcomes. Semin. Reprod. Med. 2002; 20 (02): 103–112. PubMed Abstract | Publisher Full Text 65. Lyu X, Yan K, Wang X, et al. : A novel anti-obesity mechanism for liraglutide by improving adipose tissue leptin resistance in high-fat diet-fed obese mice. Endocr. J. 2022; 69 (10): 1233–1244. PubMed Abstract | Publisher Full Text 66. Polak K, Czyzyk A, Simoncini T, et al. : New markers of insulin resistance in polycystic ovary syndrome. J. Endocrinol. Investig. 2017; 40 (1): 1–8. PubMed Abstract | Publisher Full Text | Free Full Text 67. Elkind-Hirsch KE, Chappell N, Shaler D, et al. : Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil. Steril. 2022; 118 (2): 371–381. PubMed Abstract | Publisher Full Text 68. Livadas S, Androulakis I, Angelopoulos N, et al. : Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome. Endocrinol. Diabetes Metab. Case Rep. 2020; 2020 : 19–0150. PubMed Abstract | Publisher Full Text | Free Full Text 69. Zhang X, Jiang J, Xu J, et al. : Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes. BMC Musculoskelet. Disord. 2024; 25 (1): 601. PubMed Abstract | Publisher Full Text | Free Full Text 70. Zhao T, Chen H, Cheng C, et al. : Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1. Biomed. Pharmacother. 2019; 118 : 109224. PubMed Abstract | Publisher Full Text 71. Huang L, Lin T, Shi M, et al. : Liraglutide suppresses production of extracellular matrix proteins and ameliorates renal injury of diabetic nephropathy by enhancing Wnt/β-catenin signaling. Am. J. Physiol. Renal Physiol. 2020; 319 (3): F458–F468. PubMed Abstract | Publisher Full Text 72. Huang L, Lin T, Shi M, et al. : Liraglutide ameliorates inflammation and fibrosis by downregulating the TLR4/MyD88/NF-κB pathway in diabetic kidney disease. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2024; 327 (4): R410–R422. PubMed Abstract | Publisher Full Text | Free Full Text 73. Yamada S, Tanabe J, Ogura Y, et al. : Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats. Clin. Exp. Nephrol. 2021; 25 (4): 365–375. PubMed Abstract | Publisher Full Text 74. Sun L, Yuan Y, Li Y, et al. : Effect of liraglutide on atherosclerosis in patients with impaired glucose tolerance: A double-blind, randomized controlled clinical trial. Exp. Ther. Med. 2023; 25 (6): 249. PubMed Abstract | Publisher Full Text | Free Full Text 75. Hygum K, Harsløf T, Jørgensen NR, et al. : Bone resorption is unchanged by liraglutide in type 2 diabetes patients: a randomised controlled trial. Bone. 2020; 132 : 115197. PubMed Abstract | Publisher Full Text 76. Cheng H, Zhang Z, Zhang B, et al. : Enhancement of impaired olfactory neural activation and cognitive capacity by liraglutide, but not dapagliflozin or acarbose, in patients with type 2 diabetes: A 16-week randomized parallel comparative study. Diabetes Care. 2022; 45 (5): 1201–1210. PubMed Abstract | Publisher Full Text 77. Li Y, Bader M, Tamargo I, et al. : Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice. J. Neurochem. 2015; 135 (6): 1203–1217. PubMed Abstract | Publisher Full Text | Free Full Text 78. Zhu H, Zhang Y, Shi Z, et al. : The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci. Rep. 2016; 6 : 26859. PubMed Abstract | Publisher Full Text | Free Full Text 79. He W, Tian X, Lv M, et al. : Liraglutide protects neurite outgrowth of cortical neurons under oxidative stress though activating the Wnt pathway. J. Stroke Cerebrovasc. Dis. 2018; 27 (10): 2696–2702. PubMed Abstract | Publisher Full Text 80. Zhang D, Yu D, Mei X, et al. : Liraglutide provides neuroprotection by regulating autophagy through the AMPK-FOXO3 signaling pathway in a spinal contusion injury rat model. Neurosci. Lett. 2020; 720 : 134747. PubMed Abstract | Publisher Full Text 81. Zeng S, Bai J, Jiang H, et al. : Treatment with liraglutide exerts neuroprotection after hypoxic–ischemic brain injury in neonatal rats via the PI3K/AKT/GSK3β pathway. Front. Cell. Neurosci. 2020; 13 : 585. PubMed Abstract | Publisher Full Text | Free Full Text 82. Hansen HH, Fabricius K, Barkholt P, et al. : The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer’s disease. J Alzheimer’s Dis. 2015; 46 (4): 877–888. PubMed Abstract | Publisher Full Text | Free Full Text 83. McClean PL, Hölscher C: Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014; 76 (Part A): 57–67. PubMed Abstract | Publisher Full Text 84. Shawki SM, Saad MA, Rahmo RM, et al. : Liraglutide improves cognitive and neuronal function in 3-NP rat model of Huntington’s disease. Front. Pharmacol. 2021; 12 : 731483. PubMed Abstract | Publisher Full Text | Free Full Text 85. Aboeldalyl S, James C, Seyam E, et al. : The role of chronic inflammation in polycystic ovarian syndrome—a systematic review and meta-analysis. Int. J. Mol. Sci. 2021; 22 (5): 2734. PubMed Abstract | Publisher Full Text | Free Full Text 86. Zhao M, Liao B, Yun C, et al. : Liraglutide improves follicle development in polycystic ovary syndrome by inhibiting CXCL10 secretion. Reprod. Biol. Endocrinol. 2024; 22 (1): 98. PubMed Abstract | Publisher Full Text | Free Full Text 87. Savchenko LG, Digtiar NI, Selikhova LG, et al. : Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom. J. Intern. Med. 2019; 57 (3): 233–240. PubMed Abstract | Publisher Full Text 88. Rui L, Aguirre V, Kim JK, et al. : Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser 307 via distinct pathways. J. Clin. Invest. 2001; 107 (2): 181–189. PubMed Abstract | Publisher Full Text | Free Full Text 89. Alharbi SH: Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther. Adv. Endocrinol. Metab. 2024; 15 : 20420188231222367. PubMed Abstract | Publisher Full Text | Free Full Text 90. Zhang Y, Lin Y, Li G, et al. : Glucagon-like peptide-1 receptor agonists decrease hyperinsulinemia and hyperandrogenemia in dehydroepiandrosterone-induced polycystic ovary syndrome mice and are associated with mitigating inflammation and inducing browning of white adipose tissue. Biol. Reprod. 2023; 108 (6): 945–959. PubMed Abstract | Publisher Full Text | Free Full Text 91. Liang J, Gao Y, Feng Z, et al. : Reactive oxygen species and ovarian diseases: antioxidant strategies. Redox Biol. 2023; 62 : 102659. PubMed Abstract | Publisher Full Text | Free Full Text 92. Fan D, Zhang Y, Lu L, et al. : Uncovering the potential molecular mechanism of liraglutide to alleviate the effects of high glucose on myoblasts based on high-throughput transcriptome sequencing technique. BMC Genomics. 2024; 25 (1): 159. PubMed Abstract | Publisher Full Text | Free Full Text 93. Zhang Y, Zhou H, Wu W, et al. : Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca(2+)-XO-ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways. Free Radic. Biol. Med. 2016; 95 : 278–292. PubMed Abstract | Publisher Full Text 94. Saber SM, Abd El-Rahman HA: Liraglutide treatment effects on rat ovarian and uterine tissues. Reprod. Biol. 2019; 19 (3): 237–244. PubMed Abstract | Publisher Full Text 95. Clemente-Suárez VJ, Redondo-Flórez L, Rubio-Zarapuz A, et al. : Microbiota implications in endocrine-related diseases: from development to novel therapeutic approaches. Biomedicines. 2024; 12 (1): 1. PubMed Abstract | Publisher Full Text | Free Full Text 96. Insenser M, Murri M, del Campo R , et al. : Gut microbiota and the polycystic ovary syndrome: influence of sex, sex hormones, and obesity. J. Clin. Endocrinol. Metab. 2018; 103 (7): 2552–2562. PubMed Abstract | Publisher Full Text 97. Torres PJ, Siakowska M, Banaszewska B, et al. : Gut microbial diversity in women with polycystic ovary syndrome correlates with hyperandrogenism. J. Clin. Endocrinol. Metab. 2018; 103 (4): 1502–1511. PubMed Abstract | Publisher Full Text | Free Full Text 98. Yang YL, Zhou WW, Wu S, et al. : Intestinal flora is a key factor in insulin resistance and contributes to the development of polycystic ovary syndrome. Endocrinology. 2021; 162 (10): bqab118. PubMed Abstract | Publisher Full Text | Free Full Text 99. Shang J, Liu F, Zhang B, et al. : Liraglutide-induced structural modulation of the gut microbiota in patients with type 2 diabetes mellitus. PeerJ. 2021; 9 : e11128. PubMed Abstract | Publisher Full Text | Free Full Text 100. Acharya A, Shetty SS, Kumari N, et al. : Role of gut microbiota derived short chain fatty acid metabolites in modulating female reproductive health. Hum. Nutr. Metab. 2024; 36 : 200256. Publisher Full Text 101. Zhao L, Qiu Y, Zhang P, et al. : Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet. Front. Nutr. 2022; 9 : 1048693. PubMed Abstract | Publisher Full Text | Free Full Text 102. Xiong C, Wu J, Ma Y, et al. : Effects of glucagon-like peptide-1 receptor agonists on gut microbiota in dehydroepiandrosterone-induced polycystic ovary syndrome mice: compared evaluation of liraglutide and semaglutide intervention. Diabetes. Metab. Syndr. Obes. 2024; 17 : 865–880. PubMed Abstract | Publisher Full Text | Free Full Text 103. Bridgeman SC, Northrop W, Melton PE, et al. : Butyrate generated by gut microbiota and its therapeutic role in metabolic syndrome. Pharmacol. Res. 2020; 160 : 105174. PubMed Abstract | Publisher Full Text 104. Van Deuren T, Blaak EE, Canfora EE, et al. : Butyrate to combat obesity and obesity-associated metabolic disorders: current status and future implications for therapeutic use. Obes. Rev. 2022; 23 (10): e13498. PubMed Abstract | Publisher Full Text | Free Full Text 105. Coppola S, Avagliano C, Calignano A, et al. : The protective role of butyrate against obesity and obesity-related diseases. Molecules. 2021; 26 (3): 682. PubMed Abstract | Publisher Full Text | Free Full Text 106. Schenk S, Harber MP, Shrivastava CR, et al. : Improved insulin sensitivity after weight loss and exercise training is mediated by a reduction in plasma fatty acid mobilization, not enhanced oxidative capacity. J. Physiol. 2009; 587 (Pt 20): 4949–4961. PubMed Abstract | Publisher Full Text | Free Full Text 107. Cadagan D, Khan R, Amer S, et al. : Thecal cell sensitivity to luteinizing hormone and insulin in polycystic ovarian syndrome. Reprod. Biol. 2016; 16 (1): 53–60. PubMed Abstract | Publisher Full Text 108. Zhang H, Qiu W, Zhou P, et al. : Obesity is associated with SHBG levels rather than blood lipid profiles in PCOS patients with insulin resistance. BMC Endocr. Disord. 2024; 24 : 254. PubMed Abstract | Publisher Full Text | Free Full Text 109. Frøssing S, Nylander M, Chabanova E, et al. : Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial. Diabetes. Obes. Metab. 2018; 20 (1): 215–218. Publisher Full Text 110. Xing C, Zhao H, Zhang J, et al. : Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. Front. Endocrinol (Lausanne). 2022; 13 : 945609. PubMed Abstract | Publisher Full Text | Free Full Text 111. Qu X, Donnelly R: Sex hormone-binding globulin (SHBG) as an early biomarker and therapeutic target in polycystic ovary syndrome. Int. J. Mol. Sci. 2020; 21 (21): 8191. PubMed Abstract | Publisher Full Text | Free Full Text 112. Pellatt L, Hanna L, Brincat M, et al. : Granulosa cell production of anti-müllerian hormone is increased in polycystic ovaries. J. Clin. Endocrinol. Metab. 2007; 92 (1): 240–245. Publisher Full Text 113. Barbotin AL, Peigné M, Malone SA, et al. : Emerging roles of anti-müllerian hormone in hypothalamic-pituitary function. Neuroendocrinology. 2019; 109 (3): 218–229. PubMed Abstract | Publisher Full Text | Free Full Text 114. Zhao H, Guo Y: Effects of liraglutide on leptin promoter methylation in ovarian granulosa cells of patients with polycystic ovary syndrome and obesity. Gynecol. Obstet. Investig. 2024; 90 : 1–12. PubMed Abstract | Publisher Full Text 115. Sun Z, Li P, Wang X, et al. : GLP-1/GLP-1R signaling regulates ovarian PCOS-associated granulosa cells proliferation and antiapoptosis by modification of forkhead box protein O1 phosphorylation sites. Int. J. Endocrinol. 2020; 2020 : 1484321. PubMed Abstract | Publisher Full Text | Free Full Text 116. Ji S, Yang H, Ji Y, et al. : Liraglutide improves PCOS symptoms in rats by targeting FDX1. Reprod. Sci. 2024; 31 (7): 2049–2058. PubMed Abstract | Publisher Full Text 117. Jensterle M, Salamun V, Kocjan T, et al. : Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. J. Ovarian Res. 2015; 8 (1): 32. PubMed Abstract | Publisher Full Text | Free Full Text 118. Nylander M, Frøssing S, Clausen HV, et al. : Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod. Biomed. Online. 2017; 35 (1): 121–127. PubMed Abstract | Publisher Full Text 119. Gu J, Meng X, Guo Y, et al. : The efficacy and safety of liraglutide added to metformin in patients with diabetes: a meta-analysis of randomized controlled trials. Sci. Rep. 2016; 6 : 32714. PubMed Abstract | Publisher Full Text | Free Full Text 120. Keskin L, Yaprak B: Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with type 2 diabetes mellitus. Eur. Rev. Med. Pharmacol. Sci. 2022; 26 (18): 6813–6820. PubMed Abstract | Publisher Full Text 121. Jensterle Sever M, Kocjan T, et al. : Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. Eur. J. Endocrinol. 2014; 170 (3): 451–459. PubMed Abstract | Publisher Full Text | Free Full Text 122. Long X, Liu H, Xiong W, et al. : Low dose of liraglutide combined with metformin leads to a significant weight loss in Chinese Han women with polycystic ovary syndrome: a retrospective study. Gynecol. Endocrinol. 2023; 39 (1): 2223648. PubMed Abstract | Publisher Full Text 123. Salamun V, Jensterle M, Janez A, et al. : Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur. J. Endocrinol. 2018; 179 (1): 1–11. PubMed Abstract | Publisher Full Text 124. Schulte MMB, Tsai J, Moley KH: Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod. Sci. 2015; 22 (1): 6–14. PubMed Abstract | Publisher Full Text | Free Full Text 125. Tavares ACM, Martins MYM, de Souza GF , et al. : Immunological effects of GLP-1 analogs on female reproduction: therapeutic perspectives for infertility and recurrent pregnancy loss. J. Reprod. Immunol. 2025; 169 : 104538. PubMed Abstract | Publisher Full Text 126. Usach I, Martinez R, Festini T, et al. : Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv. Ther. 2019; 36 (11): 2986–2996. PubMed Abstract | Publisher Full Text | Free Full Text 127. Chen N, Zeng Z, Chen H, et al. : Enhanced transdermal delivery of liraglutide for sustained obesity management. Langmuir. 2025; 41 (19): 12189–12198. PubMed Abstract | Publisher Full Text 128. Ziebarth J, Mainardes RM: Preparation, characterization and in vitro evaluation of chitosan nanoparticles for the oral delivery of GLP-1 analog liraglutide. J. Therm. Anal. Calorim. 2023; 148 (6): 2443–2455. Publisher Full Text 129. Seo YG: Side effects associated with liraglutide treatment for obesity as well as diabetes. J. Obes. Metab. Syndr. 2021; 30 (1): 12–19. PubMed Abstract | Publisher Full Text | Free Full Text 130. Levi J, Wang J, Venter F, et al. : Estimated minimum prices and lowest available national prices for antiobesity medications: improving affordability and access to treatment. Obesity (Silver Spring). 2023; 31 (5): 1270–1279. PubMed Abstract | Publisher Full Text 131. Sandhya Kumari MV, Kalthur G, Shetty S, et al. : Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence. BioStudies. 2025; S-BSST2135. Reference Source Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 24 Sep 2025 ADD YOUR COMMENT Comment Author details Author details 1 Division of Reproductive Biology, Department of Reproductive Science, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India 2 Embryotoxicology Laboratory, Environmental Toxicology Group, Indian Institute of Toxicology Research- (CSIR-IITR), Lucknow, Uttar Pradesh, 226001, India 3 Sree Mookambika Centre for Research and Innovation, Sree Mookambika Institutes, Padanilam, Kulasekharam, Tamil Nadu, 629161, India Shravya Shetty Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing Mouna Bannur Karunakara Roles: Investigation, Methodology, Writing – Review & Editing Ravi Ram Kristipati Roles: Methodology, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Guruprasad Kalthur Roles: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Review & Editing Sandhya Kumari Roles: Conceptualization, Funding Acquisition, Methodology, Project Administration, Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information The work is funded by the Indian Council of Medical Research, Government of India (Grant no. DDR/IIRP-23/1021). Sandhya Kumari M V. acknowledges partial support from intramural grant, Manipal Academy of Higher Education, Manipal. Dr. TMA Pai scholarship, Manipal Academy of Higher Education, Manipal awarded to Shravya Shetty is thankfully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 24 Apr 2026, 14:979 https://doi.org/10.12688/f1000research.167998.2 version 1 Published: 24 Sep 2025, 14:979 https://doi.org/10.12688/f1000research.167998.1 Copyright © 2026 Shetty S et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Shetty S, Bannur Karunakara M, Kristipati RR et al. Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.12688/f1000research.167998.2 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 24 Sep 2025 Views 0 Cite How to cite this report: V G DA. Reviewer Report For: Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.5256/f1000research.185150.r455513 ) The direct URL for this report is: https://f1000research.com/articles/14-979/v1#referee-response-455513 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 25 Feb 2026 Dr. Abilash V G , Vellore Institute of Technology (VIT), Vellore, Tamilnadu, India Approved with Reservations VIEWS 0 https://doi.org/10.5256/f1000research.185150.r455513 The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive ... Continue reading READ ALL The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. The concluding statements should more carefully reflect these uncertainties and emphasize the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Is the topic of the review discussed comprehensively in the context of the current literature? Partly Are all factual statements correct and adequately supported by citations? Partly Is the review written in accessible language? Yes Are the conclusions drawn appropriate in the context of the current research literature? Partly Competing Interests: No competing interests were disclosed. Reviewer Expertise: Reproductive Biology, Biomedical Genetics I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT V G DA. Reviewer Report For: Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.5256/f1000research.185150.r455513 ) The direct URL for this report is: https://f1000research.com/articles/14-979/v1#referee-response-455513 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 24 Apr 2026 Sandhya Kumari M V , Division of Reproductive Biology, Department of Reproductive Science, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, 576104, India 24 Apr 2026 Author Response Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important ... Continue reading Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. We would like to express our gratitude to the Reviewer for their critical assessment of this manuscript. We are pleased that the Reviewer found the research both timely and clinically relevant. Below, we provide comprehensive responses to each point raised and hope the revised version will now meet the criteria for publication. 1. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. Response: We thank the reviewer for this critical assessment. We acknowledge that the initial description did not sufficiently detail the selection workflow or the criteria for evidence evaluation required for a reproducible study. In response, we have revised the methodology of the manuscript to clarify that this work is a narrative review. which intends to provide a comprehensive synthesis of the complex 'mechanistic orchestra' between liraglutide, obesity, and PCOS. To enhance methodological transparency, we have updated the 'Methods' section to include a structured, hierarchical selection workflow, defined temporal limits (inception to March 2025), and a clear rationale for the inclusion of the articles that form the core of our translational analysis. We have updated the methodology to state that, to minimize the bias, the literature survey including the title, abstract and the full text screening, was conducted independently by two researchers. 2. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. Response: We thank the reviewer for the constructive criticism regarding the transparency of the literature selection process. We recognise that a more formalised approach is essential for the credibility of the review. To address this, we have implemented the following revisions. (1) Temporal limits are re-specified to give methodological clarity. (2) We have described the narrative justification of the workflow, and PRISMA-style flow description, as the manuscript is a narrative review. This will ensure the credibility and replicability of the literature search of the work. 3. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Response: We thank the reviewer for the pivotal critique. We recognise that the initial draft leaned more towards the descriptive summary, with the mention of limitations. We have revised the ‘’Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women’’ section to align with the analytical framework as suggested by explicitly discussing heterogeneity and confounding factors. We have restructured the discussion to clearly distinguish between preclinical mechanistic pathways and clinically validated outcomes clearly. This ensures that the potential of Liraglutide is framed as plausible based on animal data, rather than proven in clinical practice. 4. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Response: We value the reviewer’s insight regarding the narrative cohesion of the review. We recognise that while liraglutide has a broad systemic effect, the extensive detailing of the same may have diluted the primary focus of the article. We address this by significantly condensing the discussion of the peripheral systemic effects. 5. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. Response: We thank the reviewer for this valuable observation. In response, we have revised the manuscript to better integrate the thematic sections by explicitly highlighting the interconnected nature of mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes. Rather than presenting these elements in isolation, the revised text emphasizes how these processes interact within a complex biological system and collectively contribute to the therapeutic effects of liraglutide. This integrated approach aims to strengthen the translational relevance of the review by linking molecular mechanisms with clinical outcomes more coherently. 6. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. Response: We thank the reviewer for this critical feedback. We have fundamentally restructured the discussion to provide a comparative framework and insights into clinical safety. To ensure the conceptual focus of the manuscript remains centred on established clinical practice and translational relevance, and the primary focus of this review is the potential of liraglutide within the reproductive axis, we have included a comparative analysis with existing standard of care therapies 7. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. Response: We thank the reviewer for this critical analysis. We acknowledge that the initial conclusion may have understated the clinical uncertainties presented in the body of the article. We have revised the conclusion to adapt more tempered and balanced tone. Specifically, we have acknowledged the limitations such as brevity of trial durations of drug administration and follow-up and a major lack of longitudinal live-birth data and present it more carefully. 8. The concluding statements should more carefully reflect these uncertainties and emphasise the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Response: We acknowledge the reviewer's point regarding the need for a more balanced and neutral scholarly tone. We have substantially revised the conclusion to ensure that our final statement now explicitly weighs the robust mechanistic promise existing in preclinical models as well as clinical uncertainty. Detailed limitations and future directions are addressed in the Discussion to avoid redundancy, while the Conclusion has been streamlined to provide a concise and neutral summary. Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. We would like to express our gratitude to the Reviewer for their critical assessment of this manuscript. We are pleased that the Reviewer found the research both timely and clinically relevant. Below, we provide comprehensive responses to each point raised and hope the revised version will now meet the criteria for publication. 1. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. Response: We thank the reviewer for this critical assessment. We acknowledge that the initial description did not sufficiently detail the selection workflow or the criteria for evidence evaluation required for a reproducible study. In response, we have revised the methodology of the manuscript to clarify that this work is a narrative review. which intends to provide a comprehensive synthesis of the complex 'mechanistic orchestra' between liraglutide, obesity, and PCOS. To enhance methodological transparency, we have updated the 'Methods' section to include a structured, hierarchical selection workflow, defined temporal limits (inception to March 2025), and a clear rationale for the inclusion of the articles that form the core of our translational analysis. We have updated the methodology to state that, to minimize the bias, the literature survey including the title, abstract and the full text screening, was conducted independently by two researchers. 2. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. Response: We thank the reviewer for the constructive criticism regarding the transparency of the literature selection process. We recognise that a more formalised approach is essential for the credibility of the review. To address this, we have implemented the following revisions. (1) Temporal limits are re-specified to give methodological clarity. (2) We have described the narrative justification of the workflow, and PRISMA-style flow description, as the manuscript is a narrative review. This will ensure the credibility and replicability of the literature search of the work. 3. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Response: We thank the reviewer for the pivotal critique. We recognise that the initial draft leaned more towards the descriptive summary, with the mention of limitations. We have revised the ‘’Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women’’ section to align with the analytical framework as suggested by explicitly discussing heterogeneity and confounding factors. We have restructured the discussion to clearly distinguish between preclinical mechanistic pathways and clinically validated outcomes clearly. This ensures that the potential of Liraglutide is framed as plausible based on animal data, rather than proven in clinical practice. 4. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Response: We value the reviewer’s insight regarding the narrative cohesion of the review. We recognise that while liraglutide has a broad systemic effect, the extensive detailing of the same may have diluted the primary focus of the article. We address this by significantly condensing the discussion of the peripheral systemic effects. 5. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. Response: We thank the reviewer for this valuable observation. In response, we have revised the manuscript to better integrate the thematic sections by explicitly highlighting the interconnected nature of mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes. Rather than presenting these elements in isolation, the revised text emphasizes how these processes interact within a complex biological system and collectively contribute to the therapeutic effects of liraglutide. This integrated approach aims to strengthen the translational relevance of the review by linking molecular mechanisms with clinical outcomes more coherently. 6. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. Response: We thank the reviewer for this critical feedback. We have fundamentally restructured the discussion to provide a comparative framework and insights into clinical safety. To ensure the conceptual focus of the manuscript remains centred on established clinical practice and translational relevance, and the primary focus of this review is the potential of liraglutide within the reproductive axis, we have included a comparative analysis with existing standard of care therapies 7. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. Response: We thank the reviewer for this critical analysis. We acknowledge that the initial conclusion may have understated the clinical uncertainties presented in the body of the article. We have revised the conclusion to adapt more tempered and balanced tone. Specifically, we have acknowledged the limitations such as brevity of trial durations of drug administration and follow-up and a major lack of longitudinal live-birth data and present it more carefully. 8. The concluding statements should more carefully reflect these uncertainties and emphasise the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Response: We acknowledge the reviewer's point regarding the need for a more balanced and neutral scholarly tone. We have substantially revised the conclusion to ensure that our final statement now explicitly weighs the robust mechanistic promise existing in preclinical models as well as clinical uncertainty. Detailed limitations and future directions are addressed in the Discussion to avoid redundancy, while the Conclusion has been streamlined to provide a concise and neutral summary. Competing Interests: The author declares that there are no financial or non-financial competing interests that could have influenced the work or the interpretation of the findings. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 24 Apr 2026 Sandhya Kumari M V , Division of Reproductive Biology, Department of Reproductive Science, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, 576104, India 24 Apr 2026 Author Response Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important ... Continue reading Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. We would like to express our gratitude to the Reviewer for their critical assessment of this manuscript. We are pleased that the Reviewer found the research both timely and clinically relevant. Below, we provide comprehensive responses to each point raised and hope the revised version will now meet the criteria for publication. 1. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. Response: We thank the reviewer for this critical assessment. We acknowledge that the initial description did not sufficiently detail the selection workflow or the criteria for evidence evaluation required for a reproducible study. In response, we have revised the methodology of the manuscript to clarify that this work is a narrative review. which intends to provide a comprehensive synthesis of the complex 'mechanistic orchestra' between liraglutide, obesity, and PCOS. To enhance methodological transparency, we have updated the 'Methods' section to include a structured, hierarchical selection workflow, defined temporal limits (inception to March 2025), and a clear rationale for the inclusion of the articles that form the core of our translational analysis. We have updated the methodology to state that, to minimize the bias, the literature survey including the title, abstract and the full text screening, was conducted independently by two researchers. 2. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. Response: We thank the reviewer for the constructive criticism regarding the transparency of the literature selection process. We recognise that a more formalised approach is essential for the credibility of the review. To address this, we have implemented the following revisions. (1) Temporal limits are re-specified to give methodological clarity. (2) We have described the narrative justification of the workflow, and PRISMA-style flow description, as the manuscript is a narrative review. This will ensure the credibility and replicability of the literature search of the work. 3. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Response: We thank the reviewer for the pivotal critique. We recognise that the initial draft leaned more towards the descriptive summary, with the mention of limitations. We have revised the ‘’Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women’’ section to align with the analytical framework as suggested by explicitly discussing heterogeneity and confounding factors. We have restructured the discussion to clearly distinguish between preclinical mechanistic pathways and clinically validated outcomes clearly. This ensures that the potential of Liraglutide is framed as plausible based on animal data, rather than proven in clinical practice. 4. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Response: We value the reviewer’s insight regarding the narrative cohesion of the review. We recognise that while liraglutide has a broad systemic effect, the extensive detailing of the same may have diluted the primary focus of the article. We address this by significantly condensing the discussion of the peripheral systemic effects. 5. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. Response: We thank the reviewer for this valuable observation. In response, we have revised the manuscript to better integrate the thematic sections by explicitly highlighting the interconnected nature of mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes. Rather than presenting these elements in isolation, the revised text emphasizes how these processes interact within a complex biological system and collectively contribute to the therapeutic effects of liraglutide. This integrated approach aims to strengthen the translational relevance of the review by linking molecular mechanisms with clinical outcomes more coherently. 6. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. Response: We thank the reviewer for this critical feedback. We have fundamentally restructured the discussion to provide a comparative framework and insights into clinical safety. To ensure the conceptual focus of the manuscript remains centred on established clinical practice and translational relevance, and the primary focus of this review is the potential of liraglutide within the reproductive axis, we have included a comparative analysis with existing standard of care therapies 7. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. Response: We thank the reviewer for this critical analysis. We acknowledge that the initial conclusion may have understated the clinical uncertainties presented in the body of the article. We have revised the conclusion to adapt more tempered and balanced tone. Specifically, we have acknowledged the limitations such as brevity of trial durations of drug administration and follow-up and a major lack of longitudinal live-birth data and present it more carefully. 8. The concluding statements should more carefully reflect these uncertainties and emphasise the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Response: We acknowledge the reviewer's point regarding the need for a more balanced and neutral scholarly tone. We have substantially revised the conclusion to ensure that our final statement now explicitly weighs the robust mechanistic promise existing in preclinical models as well as clinical uncertainty. Detailed limitations and future directions are addressed in the Discussion to avoid redundancy, while the Conclusion has been streamlined to provide a concise and neutral summary. Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. We would like to express our gratitude to the Reviewer for their critical assessment of this manuscript. We are pleased that the Reviewer found the research both timely and clinically relevant. Below, we provide comprehensive responses to each point raised and hope the revised version will now meet the criteria for publication. 1. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. Response: We thank the reviewer for this critical assessment. We acknowledge that the initial description did not sufficiently detail the selection workflow or the criteria for evidence evaluation required for a reproducible study. In response, we have revised the methodology of the manuscript to clarify that this work is a narrative review. which intends to provide a comprehensive synthesis of the complex 'mechanistic orchestra' between liraglutide, obesity, and PCOS. To enhance methodological transparency, we have updated the 'Methods' section to include a structured, hierarchical selection workflow, defined temporal limits (inception to March 2025), and a clear rationale for the inclusion of the articles that form the core of our translational analysis. We have updated the methodology to state that, to minimize the bias, the literature survey including the title, abstract and the full text screening, was conducted independently by two researchers. 2. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. Response: We thank the reviewer for the constructive criticism regarding the transparency of the literature selection process. We recognise that a more formalised approach is essential for the credibility of the review. To address this, we have implemented the following revisions. (1) Temporal limits are re-specified to give methodological clarity. (2) We have described the narrative justification of the workflow, and PRISMA-style flow description, as the manuscript is a narrative review. This will ensure the credibility and replicability of the literature search of the work. 3. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Response: We thank the reviewer for the pivotal critique. We recognise that the initial draft leaned more towards the descriptive summary, with the mention of limitations. We have revised the ‘’Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women’’ section to align with the analytical framework as suggested by explicitly discussing heterogeneity and confounding factors. We have restructured the discussion to clearly distinguish between preclinical mechanistic pathways and clinically validated outcomes clearly. This ensures that the potential of Liraglutide is framed as plausible based on animal data, rather than proven in clinical practice. 4. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Response: We value the reviewer’s insight regarding the narrative cohesion of the review. We recognise that while liraglutide has a broad systemic effect, the extensive detailing of the same may have diluted the primary focus of the article. We address this by significantly condensing the discussion of the peripheral systemic effects. 5. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. Response: We thank the reviewer for this valuable observation. In response, we have revised the manuscript to better integrate the thematic sections by explicitly highlighting the interconnected nature of mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes. Rather than presenting these elements in isolation, the revised text emphasizes how these processes interact within a complex biological system and collectively contribute to the therapeutic effects of liraglutide. This integrated approach aims to strengthen the translational relevance of the review by linking molecular mechanisms with clinical outcomes more coherently. 6. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. Response: We thank the reviewer for this critical feedback. We have fundamentally restructured the discussion to provide a comparative framework and insights into clinical safety. To ensure the conceptual focus of the manuscript remains centred on established clinical practice and translational relevance, and the primary focus of this review is the potential of liraglutide within the reproductive axis, we have included a comparative analysis with existing standard of care therapies 7. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. Response: We thank the reviewer for this critical analysis. We acknowledge that the initial conclusion may have understated the clinical uncertainties presented in the body of the article. We have revised the conclusion to adapt more tempered and balanced tone. Specifically, we have acknowledged the limitations such as brevity of trial durations of drug administration and follow-up and a major lack of longitudinal live-birth data and present it more carefully. 8. The concluding statements should more carefully reflect these uncertainties and emphasise the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Response: We acknowledge the reviewer's point regarding the need for a more balanced and neutral scholarly tone. We have substantially revised the conclusion to ensure that our final statement now explicitly weighs the robust mechanistic promise existing in preclinical models as well as clinical uncertainty. Detailed limitations and future directions are addressed in the Discussion to avoid redundancy, while the Conclusion has been streamlined to provide a concise and neutral summary. Competing Interests: The author declares that there are no financial or non-financial competing interests that could have influenced the work or the interpretation of the findings. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 24 Sep 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 Version 2 (revision) 24 Apr 26 Version 1 24 Sep 25 read Dr. Abilash V G , Vellore Institute of Technology (VIT), Vellore, India Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2026 V G D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 25 Feb 2026 | for Version 1 Dr. Abilash V G , Vellore Institute of Technology (VIT), Vellore, Tamilnadu, India 0 Views copyright © 2026 V G D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. The concluding statements should more carefully reflect these uncertainties and emphasize the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Is the topic of the review discussed comprehensively in the context of the current literature? Partly Are all factual statements correct and adequately supported by citations? Partly Is the review written in accessible language? Yes Are the conclusions drawn appropriate in the context of the current research literature? Partly Competing Interests No competing interests were disclosed. Reviewer Expertise Reproductive Biology, Biomedical Genetics I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 24 Apr 2026 Sandhya Kumari M V, Division of Reproductive Biology, Department of Reproductive Science, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, 576104, India Author's response to Reviewer comments: The manuscript entitled “Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS -A critical review of the evidence” addresses an important and clinically relevant topic at the intersection of metabolic endocrinology and reproductive medicine. The growing interest in GLP-1 receptor agonists as potential adjuncts in PCOS management makes this review timely. The authors provide a broad overview of mechanistic pathways and summarize clinical observations linking liraglutide to metabolic and reproductive outcomes. However, in its present form, the manuscript requires substantial revision before it can meet the standards expected for indexing. The principal concerns relate to methodological transparency, depth of critical synthesis, conceptual focus, and interpretive balance. We would like to express our gratitude to the Reviewer for their critical assessment of this manuscript. We are pleased that the Reviewer found the research both timely and clinically relevant. Below, we provide comprehensive responses to each point raised and hope the revised version will now meet the criteria for publication. 1. Although multiple databases and general keywords are reported, the search strategy is not described in a manner that allows replication. There is no indication of structured screening procedures, eligibility assessment, or study selection workflow, nor is there any assessment of bias or study quality. Response: We thank the reviewer for this critical assessment. We acknowledge that the initial description did not sufficiently detail the selection workflow or the criteria for evidence evaluation required for a reproducible study. In response, we have revised the methodology of the manuscript to clarify that this work is a narrative review. which intends to provide a comprehensive synthesis of the complex 'mechanistic orchestra' between liraglutide, obesity, and PCOS. To enhance methodological transparency, we have updated the 'Methods' section to include a structured, hierarchical selection workflow, defined temporal limits (inception to March 2025), and a clear rationale for the inclusion of the articles that form the core of our translational analysis. We have updated the methodology to state that, to minimize the bias, the literature survey including the title, abstract and the full text screening, was conducted independently by two researchers. 2. The inclusion criteria appear subjective, and the absence of defined temporal limits further weakens methodological clarity. Even if the intention is to present a narrative review rather than a systematic one, greater transparency regarding literature identification and selection is essential. A structured reporting framework, such as a PRISMA-style flow description or an equivalent narrative justification, would significantly strengthen the credibility of the work. Response: We thank the reviewer for the constructive criticism regarding the transparency of the literature selection process. We recognise that a more formalised approach is essential for the credibility of the review. To address this, we have implemented the following revisions. (1) Temporal limits are re-specified to give methodological clarity. (2) We have described the narrative justification of the workflow, and PRISMA-style flow description, as the manuscript is a narrative review. This will ensure the credibility and replicability of the literature search of the work. 3. A more fundamental issue is that the manuscript describes itself as a critical review, yet the tone and structure remain largely descriptive. Much of the literature is summarized without rigorous appraisal of study design, limitations, or evidentiary strength. Positive findings are frequently highlighted without proportionate discussion of methodological weaknesses or conflicting data. A true critical review should interrogate heterogeneity across studies, address confounding factors, and clearly distinguish between mechanistic plausibility, preclinical inference, and clinically validated outcomes. Response: We thank the reviewer for the pivotal critique. We recognise that the initial draft leaned more towards the descriptive summary, with the mention of limitations. We have revised the ‘’Clinical trials assessing the effect of liraglutide on metabolic, hormonal, and reproductive function in obese and PCOS women’’ section to align with the analytical framework as suggested by explicitly discussing heterogeneity and confounding factors. We have restructured the discussion to clearly distinguish between preclinical mechanistic pathways and clinically validated outcomes clearly. This ensures that the potential of Liraglutide is framed as plausible based on animal data, rather than proven in clinical practice. 4. Several sections extend extensively into areas only tangentially related to reproductive outcomes, including neuroprotection, bone metabolism, and systemic inflammatory modulation across multiple organ systems. Although these discussions demonstrate breadth of knowledge, they detract from the central focus and dilute the narrative cohesion of the review. The manuscript would benefit from tighter thematic discipline, prioritizing content directly relevant to reproductive endocrinology and PCOS-associated infertility, while condensing or relocating peripheral material. Response: We value the reviewer’s insight regarding the narrative cohesion of the review. We recognise that while liraglutide has a broad systemic effect, the extensive detailing of the same may have diluted the primary focus of the article. We address this by significantly condensing the discussion of the peripheral systemic effects. 5. Another limitation lies in insufficient integration across thematic sections. Mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes are treated largely in isolation. The manuscript would be substantially improved by synthesizing these strands into a unified conceptual model linking molecular action to clinical translation. Such integration would help readers understand how mechanistic insights support or fail to support therapeutic outcomes, thereby strengthening the translational relevance of the review. Response: We thank the reviewer for this valuable observation. In response, we have revised the manuscript to better integrate the thematic sections by explicitly highlighting the interconnected nature of mechanistic pathways, microbiome modulation, hormonal regulation, and clinical outcomes. Rather than presenting these elements in isolation, the revised text emphasizes how these processes interact within a complex biological system and collectively contribute to the therapeutic effects of liraglutide. This integrated approach aims to strengthen the translational relevance of the review by linking molecular mechanisms with clinical outcomes more coherently. 6. The discussion of comparative therapies is also underdeveloped. While metformin and other anti-obesity pharmacotherapies are mentioned, there is little analytical comparison regarding efficacy, safety, accessibility, or positioning within treatment algorithms. Given that clinical decision-making involves evaluating alternatives rather than isolated interventions, a comparative framework is essential. Similarly, the discussion of safety remains relatively superficial. Adverse effects, cost barriers, and administration challenges are noted, but the manuscript does not explore reproductive safety, pregnancy outcomes, or potential long-term endocrine implications in sufficient depth. Response: We thank the reviewer for this critical feedback. We have fundamentally restructured the discussion to provide a comparative framework and insights into clinical safety. To ensure the conceptual focus of the manuscript remains centred on established clinical practice and translational relevance, and the primary focus of this review is the potential of liraglutide within the reproductive axis, we have included a comparative analysis with existing standard of care therapies 7. The conclusion section adopts a tone that appears more optimistic than warranted by the evidence presented. The manuscript itself acknowledges limitations in existing research, including short follow-up durations and incomplete reproductive outcome assessment. Response: We thank the reviewer for this critical analysis. We acknowledge that the initial conclusion may have understated the clinical uncertainties presented in the body of the article. We have revised the conclusion to adapt more tempered and balanced tone. Specifically, we have acknowledged the limitations such as brevity of trial durations of drug administration and follow-up and a major lack of longitudinal live-birth data and present it more carefully. 8. The concluding statements should more carefully reflect these uncertainties and emphasise the provisional nature of current findings. A more balanced summary would enhance the credibility and scholarly neutrality of the work. Response: We acknowledge the reviewer's point regarding the need for a more balanced and neutral scholarly tone. We have substantially revised the conclusion to ensure that our final statement now explicitly weighs the robust mechanistic promise existing in preclinical models as well as clinical uncertainty. Detailed limitations and future directions are addressed in the Discussion to avoid redundancy, while the Conclusion has been streamlined to provide a concise and neutral summary. View more View less Competing Interests The author declares that there are no financial or non-financial competing interests that could have influenced the work or the interpretation of the findings. reply Respond Report a concern V G DA. Peer Review Report For: Role of Liraglutide in weight management and reproductive health in women with obesity and PCOS- A critical review of the evidence [version 2; peer review: 1 approved with reservations] . F1000Research 2026, 14 :979 ( https://doi.org/10.5256/f1000research.185150.r455513) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://f1000research.com/articles/14-979/v1#referee-response-455513 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Role of Liraglutide in weight management...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-979/v2" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/14-979/v2&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/14-979/v2" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Shetty S et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-979/v2/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/14-979", templates : { twitter : "Role of Liraglutide in weight management and reproductive health.... Shetty S et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/14-979/v2" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/167998/197883") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "197883"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "424966": 0, "424967": 0, "424964": 0, "424965": 0, "424962": 0, "424963": 0, "424960": 0, "424961": 0, "478732": 0, "418582": 0, "418583": 0, "418580": 0, "418581": 0, "418579": 0, "418588": 0, "418586": 0, "418587": 0, "418584": 0, "418585": 0, "481447": 0, "481446": 0, "429351": 0, "481455": 0, "429358": 0, "481454": 0, "429359": 0, "481453": 0, "429356": 0, "481452": 0, "429357": 0, "481451": 0, "429354": 0, "481450": 0, "429355": 0, "481449": 0, "429352": 0, "481448": 0, "429353": 0, "452786": 0, "452784": 0, "429360": 0, "452785": 0, "447804": 0, "447805": 0, "447803": 0, "421702": 0, "421703": 0, "421701": 0, "421710": 0, "421708": 0, "421709": 0, "421706": 0, "421707": 0, "421704": 0, "421705": 0, "455513": 32, "479591": 0, "479590": 0, "479589": 0, "479588": 0, "479587": 0, "479586": 0, "437358": 0, "437359": 0, "437357": 0, "479595": 0, "479594": 0, "479593": 0, "479592": 0, "426614": 0, "426615": 0, "437364": 0, "437365": 0, "426613": 0, "437362": 0, "437363": 0, "437360": 0, "437361": 0, "424958": 0, "426622": 0, "424959": 0, "426620": 0, "426621": 0, "426618": 0, "426619": 0, "426616": 0, "426617": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "9f7f80c6-6596-4c1c-a8af-3147ff1124c9"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });